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INTRODUCTION
Introduction
The guideline for the management of hepatocellular 
carcinoma (HCC) was first developed in 2003 and revised in 
2009 by the Korean Liver Cancer Study Group (KLCSG) and 
the National Cancer Center (NCC), Korea. Since then, many 
studies on HCC have been carried out in Korea and other 
countries. In particular, a substantial body of knowledge 
has been accumulated on diagnosis, staging, and treatment 
specific to Asian characteristics, especially Koreans, 
prompting the proposal of new strategies. Accordingly, the 
new guideline presented herein was developed on the basis 
of recent evidence and expert opinions.
Target Population
The primary targets of this guideline are patients with 
suspicious or newly diagnosed HCC. This guideline provides 
recommendations for the initial treatment of patients with 
newly diagnosed HCC. Moreover, this guideline includes some 
information about residual, progressed, and recurred tumors 
following initial treatment; however, it is not main topic of 
this guideline. Furthermore, preemptive antiviral therapies 
for underlying chronic hepatitis, management of cancer 
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pain, and assessment of tumor response are also included to 
facilitate the use of the guideline in clinical practice. 
Intended Users
This revised guideline is intended to provide useful 
information and guidance for all Korean clinicians in charge 
of the diagnosis and treatment of HCC. It also provides 
trainee doctors and teachers practical information on the 
management of HCC.
Developers and Funding Source
The KLCSG proposed revising the KLCSG-NCC Korea 
Practice Guideline, and the NCC, Korea agreed. The KLCSG-
NCC Korea Practice Guideline Revision Committee (KPGRC), 
which included hepatologists, oncologists, surgeons, 
radiologists, and radiation oncologists, was subsequently 
formed (Appendix 1). All required funding was provided by 
the NCC, Korea. Each member of the HCC-KPGRC collected 
and evaluated relevant evidence, and wrote the manuscript. 
Conflicts of interests of the HCC-KPGRC members are 
summarized in Appendix 2.
Evidence Collection
The HCC-KPGRC collected and evaluated the literature 
relevant to HCC management by searching in using MEDLINE 
(up to 2014) for updated revisions. Only English and Korean 
literature was searched. The search term “hepatocellular 
carcinoma” and other keywords related to clinical 
questions shown were used (Appendix 3); these clinical 
questions contained a wide range of key topics including 
epidemiology, prevention, diagnosis, staging, treatment, 
and assessment of tumor response. 
Levels of Evidence and Grades of Recommendation
Relevant literature was systematically reviewed. The 
evidence and recommendations were graded according 
to the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) system with minor 
modifications (1-4). The levels of evidence were assessed 
on the basis of the possibility of changes in the estimate 
of clinical impact by further research, and were categorized 
as high (A), moderate (B), or low (C). For example, A-level 
evidence is similar but not identical to that from one or 
more randomized controlled trials (RCTs). If there is only a 
slight possibility of the level of evidence changing, because 
further RCTs are unlikely to be conducted, such evidence 
could be considered level A. According to the GRADE 
system, the grades of recommendation were classified 
as strong (1) or weak (2), collectively considering the 
level of evidence, quality, patient-centered outcomes, 
and socioeconomic aspects of each study. Therefore, each 
recommendation was graded on the basis of the level of 
evidence (A–C) and grades of recommendation (1 or 2) as 
follows: A1, A2, B1, B2, C1, or C2 (Table 1). This guideline 
avoided giving C2 grades.
List of Clinical Questions
The committee considered the following questions 
from four departments as key factors to be addressed in 
this guideline (Appendix 3). The committee reviewed the 
evidence and suggested recommendations through intra- 
and interdepartmental discussion.
Manuscript Review
Drafts of the revised guideline were thoroughly reviewed 
at several intradepartmental, three interdepartmental, 
and four departmental head meetings. In addition to 
the contents, methodological validity was evaluated on 
the basis of the Appraisal of Guidelines for Research and 
Evaluation II instrument (5, 6). A revised draft of the 
Table 1. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)
Quality of Evidence Criteria
High (A) Further research is unlikely to change confidence in the estimate of the clinical effect.
Moderate (B) Further research may change confidence in the estimate of the clinical effect.
Low (C) Further research is very likely to impact confidence on the estimate of clinical effect.
Strength of Recommendation Criteria
Strong (1)
Factors influencing the strength of the recommendation included the quality of the evidence, 
  presumed patient-important outcomes, and cost.
Weak (2)
Variability in preferences and values, or more uncertainty; recommendation is made with less 
  certainty, higher cost or resource consumption.
Among quality levels of evidence originally included in GRADE system, we excluded “very low quality” (D) (i.e., estimate of effect is very 
uncertain) from this guideline for convenience.
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manuscript was reviewed at an external review board 
meeting and an open symposium, and was modified further 
before publication. The external review board comprised 
eight specialists who are or were the head of the KLCSG 
or the Korean Association for the Study of the Liver 
(KASL). The final manuscript was endorsed by the board of 
executives of the KLCSG and the NCC, Korea.
Guideline Release
The revised HCC guideline was presented at Liver Week 
2014 (the KASL-KLCSG-Korean Association of Hepato-biliary 
and Pancreas Surgery-Korean Liver Transplantation Society 
meeting) on June 14, 2014. The Korean edition is available 
at http://www.klcsg.or.kr or http://ncc.re.kr.
Plan for Updates
Updates will be planned when new major evidence 
regarding the diagnosis and/or treatment of HCC is 
accumulated. 
Epidemiology
According to the central cancer registration statistics 
published in 2013, there were 218017 cases of cancer 
in Korea in 2011. Among them, 7.6% (16434) of all 
malignancies were primary liver cancer cases, ranking 
fifth in incidence (7). Regarding sex, 12189 cases were 
in men and 4274 cases were in women, making primary 
liver cancer the fourth and sixth most common cancer in 
men and women in Korea, respectively; the male:female 
ratio was 2.85:1 (7). Regarding age, primary liver cancer 
occurred most frequently in patients in their 50s (28.6%) 
followed by 60s (26.0%) and 70s (22.3%) (7). The crude 
incidence rate, i.e., the number of newly occurring cancer 
patients during the observation period among the study 
population, was 32.9 (male, 48.6; female, 17.1) per 100000 
population. According to an annual report of the 2010 
cancer registration statistics, the diagnostic code of HCC 
accounted for approximately 76.0% among all primary liver 
cancers. According to the age-standardized incidence rate, 
compensated with the mid-year population in 2000, the 
incidences of primary liver cancer occurrence were 28.9 
(male, 48.5; female, 12.6) per 100000 population in 1999 
and 22.8 (male, 36.7; female, 10.5) in 2011. This implies 
that the occurrence of primary liver cancer has decreased 
somewhat, showing an annual rate of change of -1.8%. 
However, the number of new cases of primary liver cancer in 
1999 was 13286 (male, 10027; female, 3259), and the sex 
ratio was similar to that of recent data, whereas the total 
number of cases is less than that of the recent data (Fig. 
1) (7, 8). This may reflect the age structure of the Korean 
population, as the absolute number of liver cancer cases 
is increasing, whereas the age-standardized incidence is 
decreasing (9).
Regarding regional distribution, in 1999, of HCC 
occurrence in Jeonnam, Gyeongbuk, and Gyeongnam was 
28.9, 26.8, and 26.4 per 100000 population, respectively. 
The occurrence of HCC was the lowest in Daejeon at 14.8 
per 100000 population; those in Gyeonggi and Seoul were 
18.2 and 18.7 per 100000 population, respectively. In 
2010, the regional incidences of HCC in Jeonnam, Jeju, 
Busan, Gyeongnam, Gyeongbuk, and Gangwon were 23.8, 
20.8, 20.7, 20.4, 20.1, and 19 per 100000 population, 
respectively. Regions of relative low incidence were 
Jeonbuk, Chungnam, Chungbuk, with 14.9, 15.1, and 15.6, 
respectively, as well as Seoul, Daegu, and Daejeon, each 
Pe
rs
on
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
Person/100000)
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
60
50
40
30
20
10
0
Incidence (female)
Incidence (male)
Age-standardized incidence rate (total)
Age-standardized incidence rate (male)
Age-standardized incidence rate (female)
Fig. 1. Annual cases and incidence rate of hepatocellular 
carcinoma (8).
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with 15.9 per 100000 population (8, 9).
In 2011, the national primary liver cancer prevalence 
was 47697 (age-standardized prevalence, 67.1 per 100000 
population), ranking sixth after thyroid, stomach, colon, 
breast, and lung cancers. Regarding the sex-specific 
prevalence, primary liver cancer was ranked at fourth in 
men (prevalence, 35689; age-standardized prevalence, 
107.2/100000) and ninth in women (prevalence, 
12009; age-standardized prevalence, 31.3/100000); the 
male:female prevalence ratio was 2.97:1. Regarding 5-year 
prevalence, the age-standardized prevalence of primary liver 
cancer increased: 43.0 in 2007, 45.1 in 2008, 46.1 in 2009, 
46.6 in 2010, and 47.9 per 100000 population in 2011, 
respectively (7, 8). The reason for the increasing prevalence 
of primary liver cancer despite its decreasing incidence is 
presumably because the survival rate of liver cancer patients 
is increasing (9).
Liver cancer is the main cause of death of Korean men 
in their 50s. According to the National Statistics Office of 
Korea, 22.5 people (male, 33.7; female, 11.3) per 100000 
population die annually from liver cancer. While the most 
frequent cause of death in people after the age of 40 is 
malignancy, liver cancer is the top-ranked cause of death 
in people in their 40s and 50s (10). According to a recent 
report of 10 principal cancers, shows that the 5-year cancer 
relative survival rates for liver cancer were 10.7%, 13.2%, 
20.2%, 27.3%, and 28.6% from 1993–1995, 1996–2000, 
2001–2005, 2006–2010, and 2007–2011, respectively, 
showing consistent improvement (Fig. 2). However, the 
prognosis of liver cancer remains very poor compared to the 
66.3% 5-year relative survival rates of all cancer patients 
from 2007 to 2011 in Korea (7, 8). The prognosis of HCC 
is closely related to liver function. A report from Europe 
stated that a few patients excluded from curative treatment 
study (i.e., liver resection, liver transplantation [LT], and 
percutaneous ethanol injection) showed a 3-year survival 
rate of 28% without any treatment for HCC (11). However, 
this could be considered to be a result of selection bias. In 
Korea, according to the 2003–2005 randomized registration 
of HCC (n = 4521), modified Union for International Cancer 
Control (mUICC) stages I, II, III, IVa, and IVb were 10.7%, 
33.4%, 27.7%, 10.3%, and 7.9%, respectively; the 3-/5-
year survival rates in these stages were 62.3%/52.0%, 
48.1%/36.0%, 22.3%/15.5%, 8.0%/6.5%, and 8.0%/6.1%, 
respectively (12). A recent single-center cohort study 
reports that 8.9%, 29.6%, 24.8%, 23.1%, and 13.6% of 
1972 patients with HCC from 2004 to 2009 were mUICC 
stage I, II, III, IVa, and IVb, respectively (13). The 5-year 
survival rates in stages I, II, III, IVa, and IVb were 71.1%, 
59.8%, 25.0%, 4.6%, and 2.1%, respectively, showing 
improvement in overall survival rates compared with the 
previous 2000–2003 cohort study. Improved survival rates in 
hepatitis B-related advanced HCC highlights the importance 
of antiviral therapy for hepatitis B-positive patients (13). 
The risk factors for HCC are relatively well known (14, 
15) and include chronic hepatitis B/C, liver cirrhosis, 
alcoholic liver disease, obesity- and fatty liver disease-
related diabetes mellitus (15, 16), and aflatoxin (17). In 
Korea, one study reports that the underlying liver diseases 
of HCC patients included hepatitis B (72.3%), hepatitis 
C (11.6%), alcoholic liver disease in (10.4%), and non-B 
non-C hepatitis (0.7%) (12). Another study reports that 
74.6% of HCC patients were positive for hepatitis B virus 
(HBV), 9.3% were positive for hepatitis C virus (HCV), 7.4% 
were long-term alcohol abusers, and 8.7% had unidentified 
causes (probably metabolic liver disease) (13). HCC 
develops in 1–4% of cirrhotic patients annually (18) and 
eventually develops in approximately one-third of cirrhotic 
patients (19). In Korea, the number of carriers of hepatitis 
B decreased markedly because of hepatitis B vaccination 
and prevention services in vertical transmission. Although 
antiviral therapy for chronic hepatitis B and C is expected 
to further decrease the incidence of HCC, metabolic liver 
disease may increase as a cause of HCC in the future.
Prevention
The primary, secondary, and tertiary prevention of HCC 
development are defined as follows. Primary prevention 
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of HCC can be achieved by universal vaccination 
against HBV infection (20), encouragement of healthy 
lifestyles preventing obesity and alcohol abuse, and 
controlling metabolic conditions. Secondary prevention 
is the prevention of HCC development in patients with 
chronic viral hepatitis through histologic improvement 
of inflammation and fibrosis by sustained suppression or 
eradication of hepatitis virus. Finally, tertiary prevention 
involves means to prevent recurrence in HCC patients after 
curative treatment.
The World Health Organization recommends vaccination 
against HBV for all newborns and high-risk groups (21). As 
perinatal or early postnatal transmission is an important 
cause of chronic HBV infection worldwide, the first dose 
of hepatitis B vaccine should be administered as soon as 
possible after birth. Vaccination is also recommended for 
age-specific cohorts (i.e., young adolescents) and people 
with risk factors for acquiring HBV infection, including 
healthcare workers, travelers to areas where HBV-infection 
is prevalent, intravenous drug users, people with multiple 
sex partners, and adult patients who do not have hepatitis 
B surface antigen or surface antibody. However, there is 
currently no vaccination against HCV.
Antiviral therapies leading to sustained suppression of 
viral replication in chronic hepatitis B patients and inducing 
sustained virologic response in chronic hepatitis C patients 
are recommended because they prevent progression to 
cirrhosis and the development of HCC. Antiviral therapies 
should be administered according to the KASL guidelines 
for the management of chronic hepatitis B and C infections 
(22). Interferon and oral nucleos(t)ide analogues are now 
available for HBV treatment. Observational studies assessing 
the effect of interferon show a potential effect in the 
reduction of HCC incidence (23). Similarly, a RCT assessing 
the effect of lamivudine shows a significant reduction in 
HCC incidence (32 months of follow-up; lamivudine vs. 
placebo, 3.9% vs. 7.4%; p = 0.047) (24). Although HCC 
reduction after antiviral treatment remains controversial (25), 
a recent study shows significant reduction in HCC incidence 
in patients treated with entecavir (5 years of follow-up; 
entecavir vs. control, 3.7% vs. 13.7%; p < 0.001) (26).
In chronic hepatitis C patients, whether interferon 
treatment reduces HCC risk (favors reducing; treated vs. 
control, 4% vs. 38%; p = 0.002) is controversial (27). 
However, others reported no significant difference in 
HCC incidence between treated and untreated controls 
(28). The results of a meta-analysis of 4700 patients from 
20 studies suggested the risk of HCC is reduced among 
interferon-treated patients (relative risk [RR], 0.43; 95% 
confidence interval [CI], 0.33 to 0.56) (29). Furthermore, 
the risk of HCC is reduced among patients with HCV who 
achieve a sustained virological response with antiviral 
therapy compared with nonsustained virological response 
(RR, 0.35; 95% CI, 0.26 to 0.46). However, once cirrhosis 
is established, there is no conclusive evidence that 
antiviral therapy can prevent or delay the occurrence 
of HCC. Previous studies including Hepatitis C Antiviral 
Long-term Treatment against Cirrhosis (HALT-C) (30, 
31) and Evaluation of PegIntron in Control of Hepatitis 
C Cirrhosis (EPIC) studies (32) show that maintenance 
therapy with pegylated-interferon in cirrhotic patients 
does not significantly decrease the incidence of HCC; the 
study populations included in these trials were patients 
with nonresponse to prior interferon treatment. Therefore, 
additional studies are required to determine the potential 
preventive effect of monotherapy or combinations of new 
direct-acting antivirals with interferon in cirrhotic patients.
Regarding tertiary prevention for HCC, there is no 
conclusive evidence that antiviral therapy can prevent or 
delay HCC recurrence after curative treatment. Yin et al. (33) 
reported oral antiviral treatment against HBV significantly 
decreased HCC recurrence and HCC-related death after 
resection, with hazard ratios (HRs) of 0.48 (95% CI, 0.32 
to 0.70) and 0.26 (95% CI, 0.14 to 0.50), respectively. In 
a study by Chen et al. (34) that enrolled 268 patients (133 
in the interferon α-2b arm), the median recurrence-free 
survival in the interferon α-2b and control arms were 42.2 
(95% CI, 28.1 to 87.1) and 48.6 (95% CI, 25.5 to infinity) 
months, respectively (p = 0.828). A meta-analysis including 
551 patients from nine cohorts (35) shows a significant 
difference in the incidence of HCC recurrence in favor of the 
antiviral treatment group (55% vs. 58%; odds ratio [OR], 
0.59; p = 0.04) after curative treatment of HBV related-
HCC; the risk of HCC was reduced by 41% in the antiviral 
treatment group. There were also significant differences 
in favor of the antiviral treatment group with respect to 
liver-related mortality (0% vs. 8%; OR, 0.13; p = 0.02) 
and overall mortality (38% vs. 42%; OR, 0.27; p < 0.001). 
Miao et al. (36) performed a meta-analysis of the impact 
of postoperative antiviral treatment on tumor recurrence 
and survival of patients with chronic HBV or HCV infection-
related HCC after curative therapy; 1224 patients were 
included in their analysis. The estimated ORs for the 1-, 3-, 
and 5-year recurrence in HBV-related HCC were 0.59, 0.43, 
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and 0.21, respectively.
In HCV-related HCC patients, Shiratori et al. (37) report 
that the rates of second or third recurrence appeared 
to be lower in the interferon group than the untreated 
group. The 5- and 7-year survival rates of patients treated 
with interferon were of 68% and 53%, respectively; those 
of untreated patients were 48% and 23%, respectively. 
Mazzaferro et al. (38) recently reported that while no 
treatment effect was apparent on early recurrence in HCV-
positive patients, there was a significant benefit on late 
recurrence (HR, 0.3; p = 0.04). According to Miao et al. (36), 
the estimated ORs for the 1-, 3-, and 5-year recurrence in 
HCV-related HCC were significantly reduced to 0.52, 0.23, 
and 0.37, respectively. 
In addition to HBV-, HCV-, and alcohol-related chronic 
liver disease, associations between diabetes and obesity, 
with HCC were recently reported (39, 40). Policies for 
preventing HCV/HBV transmission encourage lifestyles that 
prevent obesity and alcohol abuse as well as the control 
of metabolic conditions such as diabetes. Bravi et al. (41) 
reported that coffee consumption reduced the RR of HCC 
compared to no coffee consumption: the summary RR was 
0.72 for low consumption and 0.44 for high consumption. 
Their meta-analysis indicates the risk of HCC is reduced by 
40% for any coffee consumption versus no consumption.
Recommendations (Table 2)
1) Hepatitis B vaccination is recommended for all 
newborns (A1) and high-risk individuals (i.e., HBsAg-
negative and anti-HBs-negative) (B1).
2) General preventive measures include the followings: 
prevention of HBV/HCV transmission (A1), avoidance of 
alcohol abuse, and control of metabolic disorders such as 
obesity and diabetes (C1).
3) Antiviral therapy as secondary prevention against HCC 
should follow the KASL guidelines for the management of 
chronic hepatitis B/C (A1).
4) Antiviral therapy should be considered after curative 
treatment for chronic viral hepatitis-related HCC to reduce 
the risk of recurrence (B1).
Diagnosis
The diagnosis of HCC is based on pathology or 
noninvasive criteria in high-risk groups. However, 
noninvasive criteria for HCC diagnosis vary greatly among 
guidelines. Most patients with HCC have definite risk 
factors such as HBV infection, HCV infection, and cirrhosis. 
Regular surveillance (i.e., abdominal ultrasound and serum 
α-fetoprotein [AFP]) is warranted in these high-risk groups 
(42, 43). The cost-effectiveness and survival benefit of 
patients with early HCC detected in surveillance programs 
have been documented in previous studies (44). Dynamic 
contrast-enhanced computed tomography (CT), dynamic 
contrast-enhanced magnetic resonance imaging (MRI), 
or MRI using hepatocyte-specific contrast agent (i.e., 
gadolinium ethoxybenzyl diethylenetriamine pentaacetic 
acid) are preferentially recommended if HCC is suspected in 
a surveillance program.
Serum AFP has been traditionally and widely used as a 
tumor marker of HCC. However, serum AFP level is normal in 
up to 35% of cases of small HCC and can be nonspecifically 
elevated in patients with active hepatitis or active 
hepatocyte regeneration. Although the glycosylated AFP/
total AFP ratio (AFP-L3), des-γ-carboxy prothrombin or 
protein induced by vitamin K absence-II (PIVKA-II) have 
been suggested as new tumor markers for the diagnosis 
of HCC, none have demonstrated a definite role in the 
diagnosis of HCC. A recent Japanese guideline indicates the 
combined use of tumor markers (AFP > 200 ng/mL, AFP-L3 
> 15%, or PIVKA-II > 40 mAU/mL) for the diagnosis of HCC 
(45). Several Korean retrospective studies also reported 
the clinical usefulness of these new tumor markers (46, 
47). However, further well-designed studies are warranted 
to confirm their roles in the diagnosis of HCC. If serum 
AFP level increases steadily over time, especially in 
hepatitis B patients with fully suppressed viral activity, the 
development of HCC should be suspected, and a detailed 
imaging study is strongly recommended (45, 48, 49).
As the noninvasive diagnosis of HCC mostly depends on 
imaging studies, the sensitivity and specificity of imaging 
modalities are important for accurate diagnosis. Studies 
investigating the roles of imaging techniques in patients 
undergoing LT report that the diagnostic sensitivity of 
dynamic CT is 75.0%, while those of dynamic MRI are 100% 
for HCC ≥ 2 cm in diameter but only 52% for HCC < 2 cm in 
diameter (50-52). The overall sensitivities of ultrasound, 
dynamic CT, and dynamic MRI for the noninvasive diagnosis 
of HCC are 61–67%, 68–91%, and 81–100%, respectively 
(53-55). 
If liver nodules are found during surveillance in high-risk 
groups, dynamic CT, dynamic MRI, or MRI using hepatocyte-
specific contrast agent should be performed. If the typical 
hallmark of HCC (i.e., hypervascularity in the arterial phase 
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Table 2. Summary of Recommendations of 2014 KLCSG-NCC Korea Practice Guidelines for Management of Hepatocellular Carcinoma
Topic Recommendation
Prevention
1.  Hepatitis B vaccination is recommended for all newborns (A1) and for high-risk individuals (HBsAg-negative 
and anti-HBs-negative) (B1).
2.  General preventive measures include the followings: prevention of HBV/HCV transmission (A1), avoidance of 
alcohol abuse, and control of metabolic disorders such as obesity and diabetes (C1).
3.  Antiviral therapy as secondary prevention of HCC should follow the KASL guidelines for the management of 
chronic hepatitis B/C (A1).
4.  Antiviral therapy should be considered after curative treatment for chronic viral hepatitis-related HCC in order 
to reduce the risk of recurrence (B1).
Diagnosis
1.  HCC is diagnosed on the basis of either pathology or clinical criteria in case of the high-risk group (HBV/HCV 
positive or cirrhosis) (A1).
2.  When HCC is suspected during surveillance in the high-risk group, dynamic contrast-enhanced CT/MRI or liver-
specific contrast-enhanced MRI should be performed for diagnosis (B1).
3.  In the high-risk group, HCC can be diagnosed for nodules ≥ 1 cm in diameter if one or two of the 
abovementioned imaging techniques show typical features of HCC (for the diagnosis of nodules 1–2 cm in 
diameter, two or more imaging modalities are required if a suboptimal imaging technique is used). Typical 
features of HCC include arterial phase enhancement with washout in the portal or delayed phase (B1).
4.  Nodules < 1 cm in diameter can be diagnosed as HCC in high-risk patients when all of the following conditions 
are met: typical features of HCC in two or more of the abovementioned imaging modalities and continuously 
rising serum α-fetoprotein with hepatitis activity under control (C1).
5.  Pathological diagnosis should be considered when the clinical criteria are not met or typical features of HCC 
are not present. The presence of indeterminate nodules despite imaging workup or pathologic examination 
needs to be followed up with repeated imaging and serum tumor marker analysis (B1).
6.  Limitation of radiation exposure in diagnosis and staging is not considered relevant in patients with HCC. CT 
is essential for diagnosis and follow-up in HCC patients (C1).
Staging
1.  This guideline adopts the modified Union for International Cancer Control stages as a primary staging system, 
with the Barcelona Clinic Liver Cancer staging system serving as a complementary system (B1).
Surgical resection
1.  Surgical resection is the first-line treatment for patients with intrahepatic single-nodular HCC and well-
preserved liver function classified as Child–Pugh class A, without portal hypertension or hyperbilirubinemia 
(A1).
2.  Limited resection can be selectively applied to HCC patients with liver function of Child–Pugh class A or 
superb B and with mild portal hypertension or mild hyperbilirubinemia (C1).
3.  HCC resection can be considered in patients with three or fewer intrahepatic tumors without macrovascular 
invasion, if hepatic function is well preserved (C2).
4.  Laparoscopy-assisted resection can be considered for HCC located in the lateral section of the left lobe or in 
the anterolateral segment of the right lobe (B2).
Transplantation
1.  Deceased donor liver transplantation is the first-line treatment for patients with single-nodular HCC < 5 cm in 
diameter or three or fewer nodules ≤ 3 cm in diameter (Milan criteria), which are not indicated for resection (A1).
2.  Locoregional therapies (local ablation or TACE) are recommended if the timing of transplantation is not 
predictable (B1).
3.  Downstaging (e.g., with TACE) can be considered for HCCs exceeding the criteria for transplantation (C2).
4.  Living donor liver transplantation is an effective alternative to deceased donor transplantation (B1).
5.  An expanded indication for transplantation beyond the Milan criteria can be considered in HCC cases without 
definitive vascular invasion or extrahepatic spread if other effective treatment options are inapplicable (C2).
6.  Salvage transplantation can be indicated for recurrent HCC after resection according to the same criteria as for 
first-line transplantation (B1).
Local ablation
1.  RFA provides survival comparable to that of resection in patients with single-nodular HCCs ≤ 3 cm in diameter 
(A2).
2.  RFA is superior to PEIT in terms of anticancer effect and survival (A1). For HCCs ≤ 2 cm in diameter, PEIT can 
be considered if RFA is unfeasible, because the outcomes of both modalities are similar (A2). 
3.  Survival outcome can be improved by combining TACE and RFA compared to RFA alone in patients with tumors 
3–5 cm in diameter if resection is unfeasible (A2).
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Table 2. Summary of Recommendations of 2014 KLCSG-NCC Korea Practice Guidelines for Management of Hepatocellular Carcinoma 
(Continued)
Topic Recommendation
Transarterial 
  chemoembolization 
  and other 
  transarterial 
  treatments
1.  TACE is recommended for patients with good performance status without major vascular invasion or 
extrahepatic spread who are ineligible for surgical resection, liver transplantation, RFA, or PEIT (A1).
2.  TACE should be performed through tumor-feeding vessels using selective/superselective techniques to 
maximize antitumor activity and minimize hepatic damage (B1).
3.  Chemoembolization using drug-eluting beads results in less systemic adverse events and has similar 
therapeutic efficacy compared with conventional TACE (B2).
4.  In case of portal vein invasion, TACE can be considered for patients with localized tumor and well-preserved 
liver function (B2).
External-beam 
  radiation therapy
1.  EBRT can be performed in HCC patients if liver functions are Child-Pugh class A or superb B and the irradiated 
total liver volume receiving ≥ 30 Gy is ≤ 60% (B1).
2.  EBRT can be considered for HCC patients ineligible for surgical resection, liver transplantation, RFA, PEIT, or 
TACE (C1).
3.  EBRT can be considered for HCC patients who exhibit incomplete response to TACE when the dose-volume 
criteria in Recommendation 1 are met (B2).
4.  EBRT can be considered for HCC patients with portal vein invasion when the dose-volume criteria in 
Recommendation 1 are met (C1).
5.  EBRT is performed to alleviate symptoms caused by primary HCC or its metastases (B1).
Systemic therapies
1.  Sorafenib is indicated for HCC patients with very well-preserved liver function (Child-Pugh class A), good 
performance status, and regional lymph node or extrahepatic spread or for patients with tumor progression on 
other therapies (A1).
2.  Sorafenib is recommended for HCC patients with very well-preserved liver function (Child-Pugh class A), good 
performance status, and vascular invasion (A2).
3.  Sorafenib is considered for HCC patients with liver function Child-Pugh class superb B and good performance 
status if the above conditions 1 and 2 are satisfied (B1).
4.  Cytotoxic chemotherapy can be considered for HCC patients with advanced tumors who have with well-
preserved liver function and, with good performance status, in whom sorafenib therapy has failed (C1).
5.  Adjuvant TACE, sorafenib, or cytotoxic chemotherapy are not recommended for HCC patients treated with 
curative resection (B1).
Preemptive antiviral 
  therapy
1.  Patients should be tested for the HBsAg before starting cytotoxic chemotherapy or immunosuppressive therapy 
(A1).
2.  Preemptive antiviral therapy is recommended for HBV carriers undergoing cytotoxic chemotherapy to prevent 
reactivation (A1). Preemptive antiviral therapy is considered for HBV-infected patients receiving TACE (B1), 
hepatic arterial infusion chemotherapy (C1), surgical resection (C1), or EBRT (C1) to prevent reactivation.
3.  Antiviral treatment for HBV reactivation should follow the recommendations of the current KASL guidelines (A1).
Drug treatment for 
  cancer pain in HCC
1.  Careful consideration is required for pain management with medication in patients with HCC and underlying 
liver disease. The dosage and dosing intervals of analgesics should be determined on the basis of liver 
functions (C1).
2.  In patients with HCC and chronic liver disease, the dosage of acetaminophen should be lowered (C1) and 
NSAIDs should be used with caution (B1).
3.  In patients with HCC and chronic liver disease, opioid analgesics and their dosage should be selected carefully 
on the basis of drug metabolism and liver function (C1).
Assessment of tumor 
  response and 
  posttreatment 
  follow-up
1.  Assessment of tumor response should follow both the RECIST and modified RECIST criteria (B1).
2.  Patients with complete response after treatment should be followed up with imaging studies (i.e., dynamic 
contrast-enhanced CT/MRI or liver-specific contrast-enhanced MRI) and serum tumor markers every 2–6 
months in the first 2 years; thereafter, patients should be followed by regular checkups at individualized 
intervals (B1).
CT = computed tomography, EBRT = external-beam radiation therapy, HBsAg = hepatitis B surface antigen, HBV = hepatitis B virus, HCC 
= hepatocellular carcinoma, HCV = hepatitis C virus, KASL = Korean Association for the Study of the Liver, MRI = magnetic resonance 
imaging, NSAIDs = nonsteroidal anti-inflammatory drugs, PEIT = percutaneous ethanol injection therapy, RECIST = Response Evaluation 
Criteria in Solid Tumors, RFA = radiofrequency ablation, TACE = transarterial chemoembolization
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with washout in the portal or delayed phases) is identified 
by using the imaging techniques mentioned above, a 
nodule ≥ 1 cm in diameter can be diagnosed as HCC. Low, 
medium, and high signal intensity in the hepatocyte 
phase, T2-weighted image, and diffusion-weighted image, 
respectively, have been suggested as additional findings to 
support the diagnosis of HCC by MRI using a hepatocyte-
specific contrast agent (56, 57). However, further studies 
are required to confirm evidence on the role of these 
findings. The role of angiography in the diagnosis of HCC is 
quite limited owing to rapid advances in other noninvasive 
imaging techniques. Although contrast-enhanced 
ultrasonography has been introduced to characterize and 
localize small liver nodules (especially for radiofrequency 
ablation [RFA]), its roles in the diagnosis and staging 
of HCC remain quite limited (58). Positron emission 
tomography-CT (PET-CT) is not recommended as a primary 
diagnostic imaging method, because its diagnostic accuracy 
is relatively low, especially in patients with small HCC (59).
The accuracy of noninvasive diagnostic criteria largely 
depends on the size of the nodules. As the size of the 
nodules increases, their differentiation becomes poorer (60, 
61). As an HCC lesion grows, it begins to exhibit the typical 
hallmark of HCC, i.e., hypervascularity in the arterial phase 
with washout in the portal or delayed phases due to the 
gradual growth of tumor arteries and regression of portal 
flow (55, 61). Nowadays, small nodules < 1 cm in diameter 
showing the typical hallmark of HCC are being detected 
more frequently because of recent advances in imaging 
technologies. Many guidelines from Asia allow the diagnosis 
Table 3. Diagnosis of Hepatocellular Carcinoma
1.  Noninvasive diagnosis: in high-risk groups (i.e., HBV/HCV infection, liver cirrhosis)  
 1)  For liver nodules 1 cm found by surveillance: 
 If the typical hallmark of HCC* is identified on one or more (two or more†) imaging techniques‡
    2)  For nodules < 1 cm found by surveillance: 
 If the typical hallmark of HCC* is identified in two or more imaging techniques‡ and increased serum AFP with an increasing trend   
 over time is noted in patients with suppressed hepatitis activity 
2. Pathologic diagnosis
*Hypervascularity in arterial phase and washout in portal or delayed phase, †For 1–2-cm nodules, diagnosis should be based on 
identification of typical hallmark of HCC in one or more imaging techniques in optimal settings (Appendices 5 and 6) and in two or 
more imaging techniques in suboptimal settings, ‡Dynamic computed tomography, dynamic magnetic resonance imaging, gadolinium-
ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging magnetic resonance imaging.
AFP = α-fetoprotein, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, HCV = hepatitis C virus
Fig. 3. Diagnostic algorithm. 
*HCC radiological hallmarks include arterial phase enhancement with washout in portal or delayed phase, †For diagnosis of nodules 1–2 cm in 
diameter, two or more imaging modalities are required if suboptimal imaging technique is used. AFP = α-fetoprotein, CT = computed tomography, 
Gd-EOB-DTPA = gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, HCV = 
hepatitis C virus, MRI = magnetic resonance imaging, US = ultrasonography
Mass/nodule in US surveillance for patients  
with HBV+, HCV+, or cirrhosis+
< 1 cm
Yes
Yes
Yes
No
No
No
≥ 1 cm
HCC Biopsy or follow-up HCC
Continuously rising serum AFP level 
with hepatitis activity under control
Two positive techniques of HCC 
radiological hallmarks* in dynamic 
contrast enhanced CT/MRI or 
Gd-EOB-DTPA MRI
One or two† positive techniques of 
HCC radiological hallmarks* 
in dynamic contrast enhanced 
CT/MRI or Gd-EOB-DTPA MRI
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of HCC on the basis of these small nodules (45, 48, 62).
The pathologic diagnosis of HCC requires an adequate 
specimen through biopsy. However, biopsy is not always 
feasible because of the location of the target lesion and 
potential risk of complications such as bleeding and tumor 
seeding, especially in cirrhotic patients. The diagnostic 
sensitivity of fine-needle aspiration cytology, fine-needle 
aspiration biopsy, and core needle biopsy are reported 
to be 67% to 93% but much lower in patients with small 
HCC < 2 cm or targeting problems (63, 64). As the risk 
of tumor seeding due to needle biopsy is reported to be 
0.6% to 5.1%, the need for biopsy for patients with HCC 
curable by surgical resection is being challenged (65, 66). 
In addition, the false negativity of biopsy is reported to be 
approximately 33% (64).
The diagnosis of HCC for liver nodules detected by 
surveillance is based on noninvasive criteria or pathology 
(Table 3, Fig. 3). Noninvasive criteria can only be applied 
to high-risk groups (i.e., HBV/HCV infection and liver 
cirrhosis) and are based on imaging including dynamic CT, 
dynamic MRI, and MRI using a hepatocyte-specific contrast 
agent. Diagnosis should be based on the identification 
of the typical hallmark of HCC (i.e., hypervascularity in 
the arterial phase and washout in the portal or delayed 
phase) for liver nodules ≥ 1 cm in diameter (45, 62, 67). 
One or more imaging techniques are usually recommended 
for noninvasive diagnosis for these nodules; however, 
one or more imaging techniques are required in optimal 
settings (Appendices 5 and 6), whereas two or more are 
recommended in suboptimal settings for nodules 1–2 cm in 
diameter (58). In addition, stricter criteria are warranted for 
the diagnosis of HCC in cases of nodules < 1 cm. Diagnosis 
should be based on the combination of the identification 
of the typical hallmark of HCC in two or more imaging 
modalities and increased serum AFP with an increasing 
trend over time for liver nodules < 1 cm in patients with 
suppressed hepatitis activity (57). Biopsy should be 
considered for atypical nodules not meeting the noninvasive 
criteria. Any changes in the size or characteristics of 
nodules or serum tumor markers should be monitored if 
noninvasive or pathologic diagnosis is unfeasible for liver 
nodules in high-risk patients.
Diagnostic X-ray Radiation Exposure Dose and Risk of 
Dynamic CT in HCC Patients
A study of low-dose radiation in atomic bomb survivors 
indicates a significant increase in cancer risk even from 
acute 10–50 mSv radiation exposure (68). In addition, 
studies of occupational radiation exposure suggest 
protracted 50–100 mSv exposure can increase cancer risk 
in humans (69-71). The International Commission on 
Radiological Protection (ICRP) reports that the cancer risk 
after radiation exposure exhibits a linear-nonthreshold 
dose-response relationship (72, 73). However, there is 
no report on direct diagnostic X-ray radiation exposure-
related cancer risk. The dose of radiation exposure of 
4-phase liver dynamic CT is approximately 20–30 mSv. 
According to BEIR VII phase 2 trial by the Committee to 
Assess Heath Risks from Exposure to Low Levels of Ionizing 
Radiation, the additional lifetime attributable solid cancer 
and leukemia incidence and mortality rates are 0.148% 
and 0.09%, respectively, in 50-year-old men with 25 mSv 
X-ray radiation exposure after a 4-phase liver dynamic CT 
(74, 75). The ICRP 2007 recommendations are as follows: 
“The limitation of the dose to the individual patient is not 
recommended because it may, by reducing the effectiveness 
of the patient’s diagnosis or treatment, do more harm than 
good. The emphasis is then on the justification of the 
medical procedures and on the optimization of protection” 
(76). Thus, considering the abovementioned factors, any 
limitation of the cumulative radiation dose from CT for the 
diagnosis and follow-up evaluation of HCC is invalid.
Recommendations (Table 2)
1) HCC is diagnosed on the basis of either pathology or 
clinical criteria in case of the high-risk group (HBV/HCV 
positive or cirrhosis) (A1).
2) When HCC is suspected during surveillance in the high-
risk group, dynamic contrast-enhanced CT/MRI or liver-
specific contrast-enhanced MRI should be performed for 
diagnosis (B1).
3) In the high-risk group, HCC can be diagnosed for 
nodules ≥ 1 cm in diameter if one or two of the above-
mentioned imaging techniques show typical features of 
HCC (for the diagnosis of nodules 1–2 cm in diameter, two 
or more imaging modalities are required if a suboptimal 
imaging technique is used). Typical features of HCC include 
arterial phase enhancement with washout in the portal or 
delayed phase (B1).
4) Nodules < 1 cm in diameter can be diagnosed as HCC 
in high-risk patients when all of the following conditions 
are met: typical features of HCC in two or more of the 
above-mentioned imaging modalities and continuously 
rising serum AFP with hepatitis activity under control (C1).
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5) Pathological diagnosis should be considered when the 
clinical criteria are not met or typical features of HCC are 
not present. The presence of indeterminate nodules despite 
imaging workups or pathologic examination needs to be 
followed up with repeated imaging and serum tumor marker 
analysis (B1). 
6) Limitation of radiation exposure in diagnosis and 
staging is not considered relevant in patients with HCC. CT 
is essential for diagnosis and follow-up in HCC patients (C1).
Staging
Cancer staging plays a pivotal role in predicting prognosis 
as well as selecting the therapy to maximize survival 
potential. It also facilitates exchange of information and 
trial design. The prediction of prognosis in HCC patients 
is complex, because underlying liver function also affects 
prognosis (77, 78). Although several staging systems for 
patients with HCC have been devised, there is no worldwide 
consensus (79).
The American Joint Committee on Cancer (AJCC) has 
led a collaborative effort with the Union for International 
Cancer Control (UICC) to maintain a cancer staging system 
since 1959. This system classifies the extent of disease 
mostly on the basis of anatomic information on the extent 
of the primary tumor, regional lymph nodes, and distant 
metastases (i.e., TNM) and has been modified repeatedly. 
The KLCSG and The Korea NCC have adopted the fifth version 
of the mUICC staging system as a primary staging system 
for HCC in 2003 (Table 4) (80). Thus, the continuous use of 
this staging system since then may facilitate consistency 
in the analyses of registry data (62). The mUICC staging 
system appears more advantageous for estimating the 
prognosis of small HCC because it sets the size criterion 
to 2 cm unlike the AJCC/UICC, which used a criterion of 5 
cm (81). However, the fifth version of the mUICC staging 
system has limitations, particular its lack of extensive 
validation and different criteria compared with those of the 
current seventh AJCC/UICC TNM staging system. In addition 
to dynamic CT or MR imaging of the primary liver tumor, 
chest CT, bone, and PET-CT scans may be required to stage 
HCC. The risk of distant metastasis is low for patients with 
early-stage HCC (82); therefore, tests for the evaluation of 
extrahepatic metastasis should be carefully selected. The 
direct or indirect evaluation of portal hypertension is also 
required, especially for patients who are being considered 
for surgical resection.
The Barcelona Clinic Liver Cancer (BCLC) staging system 
includes factors for tumor stage, degree of liver function, 
and performance status of the patient. It suggests the 
most recommendable treatment modality for each stage 
and is being endorsed by the American Association for the 
Study of Liver Diseases (AASLD), the European Association 
for the Study of the Liver (EASL), and the European 
Organisation for Research and Treatment of Cancer (EORTC) 
(58, 83). However, the use of the BCLC staging system is 
limited because it contains a subjective component (i.e., 
performance status), crude evaluation of liver function (i.e., 
Child-Pugh class), and unduly simplified recommendations 
for treatment modality.
Recommendations (Table 2)
1) This guideline adopted the mUICC stages as a primary 
staging system, with the BCLC staging system serving as a 
complementary system (B1).
Treatment Overview
The ultimate goal of treatment for HCC is improvement of 
patient survival. This requires multidisciplinary treatment 
Table 4. Modified Union for International Cancer Control 
Staging System*
Stage T N M
I T1 N0 M0
II T2 N0 M0
III T3 N0 M0
IV A
T4 N0 M0
T1, T2, T3, T4 N1 M0
IV B T1, T2, T3, T4 N0, N1 M1
*Adapted from Liver Cancer Study Group of Japan (80, 81).
Criteria T1 T2 T3 T4 
1) Number of 
    tumors: 
    solitary
All three 
criteria are 
fulfilled
Two of the 
three criteria 
are fulfilled
One of the 
three criteria 
is fulfilled
None of the 
three criteria 
are fulfilled
2) Diameter of 
    the largest 
    tumor: no 
    more than 
    2 cm
3) No vascular 
    or bile duct 
    invasion: Vp0, 
    Vv0, B0
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planning including hepatology, oncology, surgery, 
diagnostic and interventional radiology, radiation oncology, 
and pathology. Therapies should be selected on the basis 
of strong evidence such as meta-analyses including RCTs, 
prospective controlled studies, and prospective large-scale 
cohort studies, all of which have survival as an endpoint. 
However, RCTs regarding HCC are limited. Therefore, 
currently available evidence should be interpreted 
cautiously. For balanced multidisciplinary treatment 
planning, objective evaluation is necessary in clinical 
practice.
The recommendations in this guideline were derived from 
the current best available evidence. Prerequisites for the 
application of these recommendations include equipment, 
trained personnel, and financial resources; considering the 
varying levels of these prerequisites among facilities, best 
and alternative options are proposed herein (Fig. 4). As the 
treatment options presented herein do not encompass all 
possible situations, specific treatments should be selected 
on the basis of tumor state, liver function, cirrhotic 
complications, and performance status. Recommendations 
for specific treatments are made on the basis of evidence 
and expert opinions, and are described in detail elsewhere 
in this guideline.
This overview summarizes treatment options for patients 
in various mUICC stages with well-preserved hepatic 
function (i.e., Child-Pugh class A) and good performance 
status, without any complications of portal hypertension. 
In addition, this guideline mainly includes initial treatment 
options for HCC at first diagnosis, without covering re-
treatments for residual tumors or recurrence after initial 
treatment.
Hepatic Resection
Hepatic resection is not only a primary treatment 
option for HCC unaccompanied by liver cirrhosis (84), 
but should also be preferentially considered even for 
HCC with cirrhosis if the liver function is expected to be 
able to tolerate surgery (85, 86). The results of hepatic 
resection for HCC have markedly improved thanks to recent 
advances in preoperative tests and surgical skills as well as 
accumulation of experience in postoperative management 
Fig. 4. First-line treatment according to 2014 KLCSG-NCC Korea 
Practice Guidelines for patients with HCC, Child-Pugh class A, 
no portal hypertension, and ECOG performance status 0–1. 
DDLT = deceased donor LT, EBRT = external-beam radiation therapy, 
ECOG = Eastern Cooperative Oncology Group, HCC = hepatocellular 
carcinoma, KLCSG = Korean Liver Cancer Study Group, LDLT = living 
donor liver transplantation, LT = liver transplantation, mUICC = 
modified Union for International Cancer Control, NCC = National 
Cancer Center, PEIT = percutaneous ethanol injection therapy, RFA = 
radiofrequency ablation, TACE = transarterial chemoembolization, VI = 
vascular or bile duct invasion
mUICC stage Best option Alternative option
I Resection
RFA
TACE
PEIT
EBRT
Single/≤ 2 cm/VI-
II Resection
RFA (tumor size ≤ 3 cm)
TACE
LT 
EBRT
Single/> 2 cm/VI-
II DDLT (within Milan criteria)
TACE
RFA (tumor number ≤ 3)
Resection
LDLT
PEIT (tumor number ≤ 3)
Multiple/≤ 2 cm/VI-
II TACE
EBRT
Sorafenib
Resection
Single/≤ 2 cm/VI+
III TACE
LT (within Milan criteria)
RFA (tumor number ≤ 3 and 
  size ≤ 3 cm)
Resection
Multiple/> 2 cm/VI-
III TACE
EBRT
Sorafenib
Resection
Single/> 2 cm/VI+
III TACE
Sorafenib
Multiple/≤ 2 cm/VI+
IVa Sorafenib TACE
Multiple/> 2 cm/VI+
IVa Sorafenib EBRT
TACE
Node+/no metastasis
IVb Sorafenib TACE
EBRT
Metastasis+
Table 5. Child-Pugh Classification
1 2 3
Albumin, g/dL > 3.5 2.8–3.5 < 2.8
Bilirubin, mg/dL < 2.0 2.0–3.0 > 3.0
Prothrombin time prolonged, sec 0–4 4–6 > 6 
Ascites None Slight Moderate
Encephalopathy, grade None 1–2 3–4
Class A ≤ 6 points, Class B = 7–9 points, Class C ≥ 10 points
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(87). Recent studies show that postoperative mortality after 
HCC resection is less than 1–3%. In addition, the 5-year 
overall and disease-free survival rates are 46–56% and 
23–32%, respectively (88-90).
Child-Pugh classification is conventionally used to 
preoperatively assess the safety of hepatic resection (Table 
5) (91). Hepatic resection is commonly performed in 
patients with Child-Pugh class A with Eastern Cooperative 
Oncology Group (ECOG) performance status 0–2 (Table 
6). However, Child-Pugh classification is an insufficient 
preoperative indicator of operability, because many patients 
can remain in Child-Pugh class A despite advanced cirrhosis 
(92, 93). Therefore, the indocyanine green 15-minute 
retention rate (ICG-R15), which was suggested in Japan, 
is evaluated at many Korean institutions as a preoperative 
test for the prediction of residual liver function (94). 
Although major hepatic resection is recommended only 
for patients with ICG-R15 ≤ 10%, some authors recently 
reported safely performing right hemihepatectomy even in 
patients with an ICG-R15 of 14% (95). On the other hand, 
portal hypertension and serum bilirubin level have been 
suggested to be important indicators for the assessment of 
resectability in Europe and the USA. Portal hypertension is 
defined as a hepatic venous pressure gradient ≥ 10 mm Hg 
(96). Esophageal varix and thrombocytopenia < 100000/
mm3 accompanied by splenomegaly are also indicators of 
portal hypertension, and thrombocytopenia is considered 
the most clinically useful (58). The posthepatectomy 
complication rate is high and the long-term prognosis is 
poor in patients with portal hypertension (96-98). However, 
some recent studies show comparable outcomes can be 
achieved even in patients with portal hypertension (99-
101). Therefore, hepatic resection can also be considered 
the primary treatment option in patients with mild portal 
hypertension if LT is unavailable. Minor hepatic resection 
less than hemihepatectomy should be considered in patients 
with mild portal hypertension, because resection volume 
is closely associated with the risk of postoperative hepatic 
insufficiency.
Assessment of future liver volume or remnant liver volume 
after resection is as important as the hepatic reservoir 
function test in order to predict postoperative hepatic 
insufficiency. HCC is accompanied by chronic liver disease 
in 80% of cases. Although 70–80% of the liver’s volume can 
be resected for normal livers, much less resection volume 
is allowed for diseased livers. There are few studies about 
the safe remnant liver volume in patients with cirrhosis. 
Nevertheless, a remnant liver volume ≥ 40% is generally 
recommended in cirrhotic patients for safety (102). Several 
noninvasive tests to measure the severity of hepatic fibrosis 
have been developed. Among them, transient elastography 
was recently reported to be effective for predicting 
postoperative hepatic failure (103-105). In the near future, 
transient elastography is expected to play an important 
role in the preoperative assessment of hepatic functional 
reservoir.
Dynamic contrast-enhanced CT is the basic test utilized as 
a preoperative radiologic study to assess the possibility of 
resection. MRI using a hepatic cell-specific contrast medium 
is superior to CT for HCC detection, especially for small HCCs 
< 1 cm (106, 107). Nevertheless, more studies are required 
to validate the value of MRI as the basic radiologic study 
for assessing resectability and formulating resection plans. 
Further postoperative examinations may be necessary to 
find extrahepatic metastases in patients with advanced 
HCC. 18F-fluoro-2-deoxyglucose (18F-FDG) PET-CT may be 
effective for investigating extrahepatic metastasis, although 
its sensitivity is very low for intrahepatic lesions (59, 108). 
In addition, chest CT and bone scan may be helpful (109).
Transarterial chemoembolization (TACE), performed 
before hepatic resection for the purpose of improving 
postoperative prognosis, is not recommended (110, 111). 
Table 6. ECOG Performance Status*
Grade ECOG
0 Fully active, able to carry out all pre-disease performance without restriction
1
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g., 
  light house work, office work
2
Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking
  hours
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot perform any self-care. Totally confined to bed or chair
5 Dead
*Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655. ECOG = 
Eastern Cooperative Oncology Group
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Some reports assert that portal vein embolization before 
extensive hepatic resection might induce compensatory 
hypertrophy of the residual liver and reduce the risk of 
surgery, especially in cases with liver cirrhosis; nonetheless, 
these are largely debatable (112, 113).
One reason why hepatic resection has recently become 
safer is the reduction in the amount of intraoperative 
hemorrhage, thus minimizing the amount of blood 
transfusion required. Blood transfusion compromises 
anticancer immunologic mechanisms and increases 
postoperative recurrence. A recent meta-analysis reports 
that intraoperative transfusion increases complication rates 
and reduces overall and disease-free survival rates after 
resection in HCC patients (114). Owing to selective hepatic 
blood flow occlusion, maintaining low central venous 
pressure, and precise transection of the hepatic parenchyma, 
the recent rate of transfusion in hepatic resection is ≤ 10% 
(115). Although some reports suggest anatomical resection 
may be superior to nonanatomical resection by securing 
the resection margin and removing micro-metastases (116), 
further confirmation is required, because the results are 
inconsistent (117). Surgery guaranteeing a tumor-free 
resection margin is absolutely critical for improving long-
term prognosis. One prospective randomized trial shows 
that a resection margin > 2 cm leads to better outcomes 
after HCC resection (118). Meanwhile, another study reports 
that the resection margin width is not important so long 
as a tumor-negative margin is guaranteed (119). Therefore, 
although sufficient margin from the tumor and anatomical 
resection are recommended during HCC resection if possible, 
considering patient safety is more important, because 
excessive hepatic resection can be fatal in patients with 
cirrhosis (116, 120, 121).
Laparoscopic hepatic resection has advanced rapidly, 
and its indications have been expanded. Many studies 
show that the efficacy and safety of laparoscopic hepatic 
resection is comparable to those of open hepatic resection 
for small HCCs located in the left lateral section or on the 
surface of the right liver (122). Although laparoscopic 
major hepatic resection is increasingly being performed as 
well, it is currently limited to only experienced surgeons. 
Accordingly, its efficacy and safety should be evaluated 
further (123). Robotic hepatic resection has recently been 
tried in very select cases, and comparative studies between 
robotic hepatic resection and open or laparoscopic hepatic 
resection are expected (124).
The best prognosis after hepatic resection is generally 
expected in cases involving 1 or 2 small tumors. Larger 
tumors are associated with a high incidence of vascular 
invasion result in poor prognosis even after resection. 
However, a recent study shows that approximately one-
third of large HCCs ≥ 10 cm have no vascular invasion and 
favorable results after resection in those cases. Therefore, 
the resectability for HCC should not be decided upon 
according to tumor size (125-127). Recent advances 
in surgical techniques and improvements in patient 
management have enabled hepatic resection in elderly 
patients with comparable short- and long-term outcomes. 
Nevertheless, major hepatic resection should be considered 
with caution, because hepatic regeneration power gradually 
decreases with age (128-130).
Although some authors reported that one-stage hepatic 
resection was an effective method for ruptured HCC in 
patients with good liver function (131), first hemostasis 
by TACE and subsequent elective surgery after accurate 
assessment of hepatic reservoir function would be safer 
and more effective in hemodynamically unstable patients 
(132, 133). However, ruptured cases have poorer long-term 
results than unruptured HCC cases (134). Hepatic resection 
is generally contraindicated in cases with evident tumor 
invasion to major hepatic or portal veins. In patients with 
less hepatic fibrosis or those with a well-differentiated 
HCC of low Edmondson-Steiner grade, the 5-year survival 
rate after resection of HCC with major vascular invasion is 
reported to be ≥ 20% (135). Nevertheless, surgical resection 
would be at least more effective than medical treatment 
(136). According to a Korean multicenter study, the 5-year 
survival rate after resection of HCC with bile duct invasion 
was satisfactory at 32% (137). Hence, surgical resection can 
be considered even for HCC with major vascular invasion or 
bile duct invasion in select cases.
The hanging maneuver is frequently used during hepatic 
resection. However, there is no report about the effect of 
the hanging maneuver on survival or recurrence after HCC 
resection. Nevertheless, the hanging maneuver can shorten 
operative time and reduce the amount of bleeding (138). 
The anterior approach, which is often used for the resection 
of large tumors, is associated with less bleeding, a lower 
transfusion rate, and better survival in one prospective 
study (139). However, its pathologic advantages require 
further evaluation.
The 5-year recurrence rate after hepatic resection of HCC 
ranges from 58% to 81%, and 80% to 95% of postoperative 
recurrences are intrahepatic (140). Intrahepatic recurrences 
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are divided into intrahepatic metastasis and de novo HCC 
by multicentric carcinogenesis. The two recurrence entities 
can be differentiated by means of genomic hybridization, 
deoxyribonucleic acid (DNA) fingerprinting, DNA microarray, 
or HBV integration pattern (141). However, no clinical 
definition of either entity has been established. In general, 
late recurrence more than 2 years after primary resection 
is considered de novo HCC (142). Risk factors associated 
with recurrence after resection are classified as tumor-
related factors and underlying disease-related factors. 
Tumor-related risk factors, which are usually related to early 
recurrence, include tumor size and number, microvascular 
invasion, poor tumor differentiation, high serum AFP and 
PIVKA-II levels, and positivity on 18F-FDG PET. Meanwhile, 
underlying disease-related risk factors, which influence late 
recurrence, include cirrhosis, high serum HBV DNA level, and 
active hepatitis (59, 142-148). Nevertheless, no association 
between risk factors and recurrence time is evident in many 
cases, because this time-dependent classification does not 
actually reflect the tumor-pathologic mechanism of HCC 
recurrence.
Imaging modalities such as CT and MRI as well as 
serum tumor markers are recommended surveillance tools 
during follow-up. Serum AFP, a traditional tumor marker 
of HCC, is not only useful for the diagnosis of HCC, but is 
also effective for checking for recurrence after resection. 
PIVKA-II is another HCC marker with increasing utility for 
diagnosis, follow-up, and prognostication of HCC (147, 
149).
The 5-year survival rate of patients who undergo re-
resection of intrahepatic recurrence after initial surgery 
ranges from 37% to 70% (140, 150-152). Because the 
result of re-resection is excellent in cases with a long 
interval between initial surgery and tumor recurrence, re-
resection can be recommended particularly for patients with 
late intrahepatic recurrence 1–2 years after initial resection 
as long as vascular invasion of the tumor is not evident 
and liver function is tolerable to re-operation. In addition, 
salvage transplantation could result in an excellent disease-
free survival rate > 60% if the conditions of the patient 
and recurrent tumors are suitable for transplantation (153, 
154). Extrahepatic recurrence develops in 15–37% of cases 
after HCC resection, most frequently in the lungs followed 
by the abdominal cavity and bones (155). Metastatectomy 
can also be considered when the liver function can tolerate 
surgery and intrahepatic HCCs have been clearly treated or 
are controllable (156, 157).
Recommendations (Table 2)
1) Surgical resection is the first-line treatment for 
patients with intrahepatic single-nodular HCC and well-
preserved liver function of Child-Pugh class A without portal 
hypertension or hyperbilirubinemia (A1).
2) Limited resection can be selectively applied to 
HCC patients with liver function Child-Pugh class A or 
superb B and with mild portal hypertension or mild 
hyperbilirubinemia (C1).
3) HCC Resection can be considered in patients with 
three or fewer intrahepatic tumors without macrovascular 
invasion if hepatic function is well preserved (C2).
4) Laparoscopy-assisted resection can be considered 
for HCC located in the lateral section of the left lobe or 
anterolateral segment of the right lobe (B2).
Liver Transplantation
Liver transplantation (LT) is the first choice of treatment 
for patients with single tumors ≤ 5 cm or those with small 
multinodular tumors (≤ 3 nodules ≤ 3 cm) and advanced 
liver dysfunction. LT involves complete removal of a 
diseased liver including HCC and replacement with another 
liver. It is theoretically the ideal treatment method. The 
application of broad selection criteria in the early history 
of LT resulted in very poor outcomes, with a 5-year 
survival less than 40%; there was even a time when LT 
was relatively contraindicated (158, 159). However, this 
resulted in the identification of the best candidates, and 
subsequent studies with highly specific groups of patients 
report a 5-year disease-free survival rate of 74% (160, 
161). The Milan Group in Italy reports excellent results after 
LT, showing that patients with the following characteristics 
have 4-year survival and disease-free survival rates of 75% 
and 83%, respectively: 1) no extrahepatic metastasis or 
vascular infiltration in radiologic study before LT; 2) a single 
nodule ≤ 5 cm; 3) ≤ 3 nodules in cases of multiple nodules, 
with each nodule ≤ 3 cm. Accordingly, they suggest those 
criteria for LT in patients with HCC (162). Since then, the 
Milan criteria have widely been applied for LT in patients 
with HCC. A recent systematic review of 90 studies including 
a total of 17780 patients over 15 years identified the Milan 
criteria as an independent prognostic factor after LT. The 
overall 5-year survival rate of patients meeting the Milan 
criteria (65–78%) is similar to that of non-HCC patients 
according to European and American transplant registries 
(163-165).
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Recent advances in imaging technologies have enabled 
the noninvasive diagnosis of HCC with higher accuracy. 
However, small lesions that could not be detected by 
imaging studies when the Milan criteria were established 
can often be seen on imaging studies using current 
technologies, causing confusion as to whether a patient 
meets the Milan criteria or not. A recent meta-analysis 
including 22392 patients concludes that the size of the 
largest tumor and total diameter of nodules are the best 
predictors of outcome but that there is insufficient evidence 
regarding the effect of nodule number on the outcome of 
LT (166). Sugimachi et al. (167) also report poor diagnostic 
accuracy of radiologic imaging for small (< 1 cm) HCCs and 
their small effect on prognosis after LT. Therefore, lesions ≤ 
10 mm or showing atypical imaging features should not be 
considered when deciding upon LT.
Before LT, patients with HCC undergo tests for staging 
in addition to general whole-body examination. Dynamic 
contrast-enhanced CT or MRI is performed as a radiologic 
assessment of the liver itself. Extrahepatic staging should 
include chest CT, and abdominal and pelvic CT or MRI 
(168). Brain imaging and bone scintigraphy can also be 
performed. Moreover, 18F-FDG PET-CT can help clarify the 
biologic characteristics of HCC, because PET-positive tumors 
exhibit unfavorable histological features more frequently 
(e.g., high cellular dedifferentiation and microvascular 
invasion), resulting in worse recurrence-free survival after 
LT (169, 170). Although there is neither a specific study nor 
consensus on the optimal timing or modality of evaluation 
of wait-listed patients to ensure they continue to meet the 
acceptability criteria for LT, re-evaluation with a 3-month 
interval is commonly performed with dynamic CT or MRI and 
AFP measurement (171).
Deceased Donor Liver Transplantation
Deceased liver donors are always in shortage. Accordingly, 
many patients are waiting for LT at any given time. 
Patients with HCC must undergo a long waiting period 
from registration to LT. The American United Network for 
Organ Sharing (UNOS) introduced the Model for End-stage 
Liver Disease (MELD) scoring system in order to decide 
on the priority order for LT. Patients with HCC involving a 
single nodule between 2 and 5 cm or multinodular tumors 
(≤ 3 nodules ≤ 3 cm) are given the priority MELD score 
of 22 points as well as 10% additional points for every 3 
months waiting for LT; thus, similar risks of drop-out from 
the waiting-list can be expected between HCC patients 
and non-HCC candidates (172, 173). Meanwhile, Korean 
the National Organ Transplantation Management Center 
operates the Korean Network for Organ Sharing (KONOS) 
grading system (174). In this system, no additional points 
are given to patients with HCC. The provision in the KONOS 
grading system regarding patients with HCC specifies 
that cases with a Child-Turcott-Pugh score ≥ 7 points and 
simultaneously meeting the Milan criteria belong to KONOS 
grade 2B. Patients with KONOS grade 2B are pushed back 
in the priority order, and will not be able to undergo LT in 
a short time (175). According to a recent multicenter study 
in Korea (n = 1101; mean follow-up, 349 days), 23.5% 
of wait-listed patients with HCC dropped out. The most 
frequent reason for dropping out was aggravation of liver 
function (46.7%), followed by aggravation of HCC (36.3%). 
Aggravation of HCC was observed in 44.8% (241/538) of 
patients while on the waiting list; 14.2% and 48.1% of 
aggravations occurred within 1 year and between 1 and 2 
years after listing, respectively (176). The overall survival 
of patients with HCC was significantly worse than that of 
patients without HCC. The impact of HCC on the LT waiting 
list drop-out rate was significant only in patients with a 
MELD score < 20 (176, 177).
If the cutoff for the definition of a cure is a 5-year 
survival rate of 50% after LT in patients with HCC, the 
indications for LT could be expanded beyond the Milan 
criteria (178, 179). Some studies chose a 5-year survival 
rate cutoff of 70%, because it is similar to the rate 
expected for patients undergoing LT for noncancerous 
conditions and liver grafts from deceased donors (180-182). 
The University of California, San Francisco (UCSF) Group 
reports a 5-year survival rate of 75% for patients meeting 
the following criteria: 1) a single tumor ≤ 6.5 cm; 2) < 3 
nodules in multiple HCC cases, with the longest diameter < 
4.5 cm and the sum of diameters < 8 cm (183). In addition, 
the “up-to-seven criteria,” (i.e., the number 7 as the sum of 
the largest tumor diameter plus the number of tumors) have 
also been suggested; the 5-year survival rate of patients 
meeting these criteria is 71.2% (184). Microvascular 
invasion in pretransplant biopsy, tumor volume, and AFP 
levels are also considered in the expanded indications for LT 
(185, 186).
Bridging Therapy
The actuarial probability of dropping due to tumor 
progression while waiting for LT for 1 year is reported to 
range from 15% to 30% (183). Locoregional therapies are 
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reported to reduce the dropout rate to 0–25% (173, 187). 
TACE or RFA can be performed to prevent tumor progression 
(188-190). Markov-based cost-effectiveness analysis 
indicates benefits for neo-adjuvant treatments when waiting 
times exceed 6 months (188). AFP increasing > 15 μg/L/
mo while waiting for LT is the most relevant preoperative 
prognostic factor for low overall survival and disease-free 
survival (185).
The effects of neoadjuvant treatments on survival after 
LT are even more difficult to assess. Many studies report 
survival rates similar to those of untreated individuals 
(191-194); however, the major limitation of these studies 
is shorter waiting times (< 6 months) for LT (191, 192). 
The response to bridging therapy significantly affects 
both tumor recurrence and overall survival rate. This result 
suggests that HCC candidates should be prioritized with 
respect to their response to bridging therapy (195) that 
improved overall survival after LT is expected (196). The 
Organ Procurement and Transplantation Network/Scientific 
Registry of Transplant Recipients data regarding LT for HCC 
show a higher 3-year post-LT survival rate in patients who 
received ablative procedures before LT than those who did 
not regardless of pre-LT treatment modality (197). Radiation 
as a bridge to LT for advanced HCC is feasible, and well-
selected patients are expected to achieve improved overall 
survival if HCC responds (198-200).
Downstaging
Regarding downstaging, there are no RCTs, large case-
control studies, or large well-designed cohort studies in 
which patients were treated consistently and properly 
followed up. Some prospective studies suggest downstaging 
according to the Milan or UCSF criteria as a result of 
locoregional therapies achieves 5-year survival outcomes 
similar to those within the Milan or UCSF criteria (190, 
201). However, it is unclear if downstaging therapies yield 
measurable anticancer effects. Downstaging of HCC with 
TACE may be possible in 24–63% of cases (178, 196, 202, 
203). Downstaging is more effective in cases in which 
tumor size is < 7 cm or there are fewer than 3 tumors 
(203), but there is no clear upper limit for the eligibility 
of downstaging (204). Downstaging is possible with RFA 
or hepatic resection, but the efficacy of both remains 
inconclusive (187). Transarterial radioembolization (TARE) 
using Yttrium-90 (90Y) appears to outperform TACE for 
downstaging HCC from UNOS T3 to T2, and downstaged 
patients show a statistically insignificant trend toward 
improved overall survival after LT (205).
Living Donor Liver Transplantation
Patients with HCC in Korea have a very low probability of 
receiving deceased donor liver transplantation (DDLT) before 
tumor progression (206). According to the KONOS regulation 
for registration and allocation in Korea, LT recipient 
candidates with HCC cannot gain higher priority on the 
waiting list (174). These findings suggest DDLT is not a 
feasible treatment modality for patients with HCC in Korea. 
Therefore, living donor liver transplantation (LDLT) from a 
healthy donor has emerged as an alternative to DDLT as a 
treatment modality for HCC. In fact, a significant proportion 
of the LT recipients with HCC received transplantations 
from live donors in Korea. The proportion of adult LDLT 
recipients with HCC has recently increased to 30–40% in 
Korea, suggesting LDLT is now one of the main treatment 
modalities for HCC (207).
The outcome of LDLT versus DDLT for patients with HCC 
is controversial. A meta-analysis of 633 LDLTs and 1232 
DDLTs (208) indicates LDLT is an acceptable option that 
does not compromise survival rates. However, the disease-
free survival rate is worse after LDLT than DDLT. The higher 
recurrence observed after LDLT is likely due to differences 
in tumor characteristics, pretransplant HCC management, 
and waiting time (209-211). The recurrence rate with 
respect to stage is higher in recipients whose transplants 
were accelerated (i.e., “fast-tracked”) by performing 
LDLT, especially in the era in which patients with HCC are 
disadvantaged by the allocation algorithm (210). Cost-
effectiveness studies suggest LDLT can be offered to 
patients with HCC if the waiting list exceeds 7 months 
(211). Some authors recommend an observation period, 
e.g., 3 months prior to LT, in order to avoid transplantation 
in cases with potentially aggressive tumors (210). 
However, these propositions require further investigation. 
Furthermore, future studies must have better study design 
and reporting in order to accurately describe the observed 
difference in disease-free survival due to inappropriate 
study design or biological risk specifically associated with 
LDLT (208).
Several eligibility criteria besides the Milan criteria 
for LDLTs have been adopted by many high-volume LDLT 
centers. At Asan Medical Center, patients with ≤ 6 HCCs ≤ 
5 cm and without gross vascular invasion are considered 
eligible for LT; such patients have a 5-year survival rate 
of 81.6% at this center (212). At Seoul Catholic Medical 
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Center, LDLT is considered the preferred therapeutic option 
in patients with an AFP level < 100 ng/mL and a tumor 
diameter < 5 cm. The 5-year disease-free survival and 
overall survival rates after LDLT in all patients with HCC are 
80.9% and 76.4%, respectively (213). At Seoul National 
University Hospital, the 3-year survival rate is reported to 
be 86.2% if vascular invasion was absent in preoperative 
radiological studies and preoperative AFP was < 400 ng/
mL (214). At Samsung Medical Center, patient selection 
according to tumor size < 5 cm and AFP < 400 ng/mL 
without limitation of tumor number expanded patient 
selection; 1-, 3-, and 5-year survival rates are reported 
to be 92.2, 82.6, and 79.9%, respectively (215). In the 
selection of HCC patients for LT, the University of Tokyo has 
adopted the 5-5 rule, i.e., HCC ≤ 5 cm and ≤ 5 in number, 
and a recurrence-free survival rate of 94% after LT was 
achieved (216). Kyoto University further extended the 
number of tumors to 10 with serum PIVKA-II levels ≤ 400 
mAU/mL; the resultant 5-year survival rate was 86.7% (217). 
At Kyushu University, a 5-year survival rate of 82.7% was 
achieved in patients with HCCs ≤ 5 cm and serum PIVKA-II 
levels < 300 mAU/mL (218). In a study involving 49 centers 
and 653 patients in Japan, patients with HCCs beyond the 
Milan criteria but with serum AFP levels ≤ 200 ng/mL and 
serum PIVKA-II levels ≤ 100 mAU/mL had a 5-year disease-
free survival rate of 84.3% (219).
Living donor liver transplantation (LDLT) has been 
proposed as an ideal setting for exploring expanded 
indications for HCC, considering a lack of graft allocation 
and priority policies. Moreover, the graft of a live donor is 
a personal gift. If the posttransplant outcomes of several 
eligible criteria beyond the Milan criteria for LDLTs are 
comparable to those with the Milan criteria, expanded 
indications can be accepted as long as the safety of the live 
donor is ensured. The 5-year overall and disease-free survival 
rates of expanded indications beyond the Milan criteria for 
LDLTs exceed 80% and 70%, respectively (220-222).
The outcomes of live donors (n = 2872 published cases) 
from Korea are excellent (223-228). The risks and benefits 
of LDLT should take into account both the donor and 
recipient; this concept is known as “double equipoise.” 
The associated probabilities of death and life-threatening 
complications in LDLT for healthy donors are reported to be 
0.3% and < 2%, respectively (220-222, 229). Because of 
the complexity of the procedure, LDLT must be restricted to 
centers of excellence in hepatic surgery and LT to minimize 
donor risk and maximize recipient outcome. Careful 
attention should be given to the psychosocial aspects of 
live donors.
Salvage Liver Transplantation
Salvage liver transplantation (SLT) is promoted as a 
potential curative treatment strategy for HCC recurrence 
following primary liver resection with curative intent 
(230). This strategy may reduce disease progression in 
patients waiting for LT and may also reduce the number of 
transplants required. An intention-to-treat analysis shows 
that LT for patients with small resectable HCCs yields 
survival outcomes superior to those of liver resection (231-
233). Nevertheless, patients with small resectable HCCs 
are offered liver resection rather than LT because of the 
aforementioned organ shortage (234).
Patients with HCCs beyond as well as within the Milan 
criteria should be initially treated with liver resection and 
can later be salvaged with LT if they develop recurrent HCC 
within the Milan criteria and is not too aggressive (153). 
The selection criteria for SLT are same as those for primary 
LT (153, 154, 232, 235-239). This is because the risk factors 
for HCC recurrence after SLT are similar to those of primary 
LT (236, 240). Significant independent risk factors for HCC 
recurrence after SLT include microscopic vascular invasion, 
poor differentiation, satellite nodules, high AFP level, and 
tumor size and number. Extension beyond the Milan criteria 
and avoiding risk factors are also important issues regarding 
SLT. Furthermore, prophylactic or preemptive SLT before HCC 
recurrence for patients with risk factors for recurrence after 
hepatic resection remains controversial in light of the organ 
shortage. Another concern is the potential for surgical 
difficulty following prior resection and postoperative 
complications, which may negate the benefit of an SLT. 
Meta-analyses and systemic reviews (154, 234, 241) show 
that the recipient outcomes of SLT are similar to those of 
primary LT with respect to overall and disease-free survival.
For patients who develop recurrent HCC after primary 
hepatic resection but have a very low probability of 
receiving DDLT before tumor progression, salvage LDLT 
could be a curative treatment option like primary LT. The 
indications and selection criteria for salvage LDLT are same 
as those for primary LDLT (153, 236-239).
Posttransplantation Immunosuppression
A calcineurine inhibitor-based immunosuppressant is 
generally administered in HCC patients after LT (242). 
Sirolimus was recently reported to suppress HCC recurrence 
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via an antiproliferation effect (243, 244) contributing to 
improved survival (245). However, this finding must be 
corroborated by additional studies.
Recommendations (Table 2)
1) DDLT is the first-line treatment for patients with 
single-nodular HCC < 5 cm in diameter or 3 or fewer ≤ 3 
nodules ≤ 3 cm in diameter (Milan criteria), which are not 
indicated for resection (A1).
2) Locoregional therapies (local ablation or TACE) are 
recommended if the timing of transplantation is not 
predictable (B1).
3) Downstaging (e.g., with TACE) can be considered for 
HCCs exceeding the criteria for transplantation (C2).
4) LDLT is an effective alternative to deceased donor 
transplantation (B1).
5) An expanded indication for transplantation beyond 
the Milan criteria can be considered in HCC cases without 
definitive vascular invasion or extrahepatic spread, if other 
effective treatment options are not inapplicable (C2).
6) Salvage transplantation can be indicated for recurrent 
HCC after resection according to the same criteria as for 
first-line transplantation (B1).
Locoregional Therapies
Locoregional therapies are widely performed as 
nonsurgical treatments for HCC because of their convenience 
and relatively lower invasiveness. Although TACE can be 
considered a locoregional therapy in a broad sense, it 
will not be discussed here. RFA and percutaneous ethanol 
injection therapy (PEIT) are the current standard local 
therapies, while others such as microwave ablation, laser 
ablation, cryoablation, acetic acid injection therapy, and 
high-intensity focused ultrasound are currently undergoing 
clinical trials.
The indications for locoregional therapies include patients 
with a single HCC nodule ≤ 5 cm or up to 3 nodules ≤ 3 
cm, although they vary among studies. The effectiveness 
of local therapies depends on tumor size, while complete 
tumor necrosis rates are reported to exceed 80% for tumors 
< 3 cm (246). Predictors of survival include initial complete 
tumor necrosis, Child-Pugh score, tumor size and number, 
and baseline serum AFP level. In particular, local therapies 
are very effective for Child-Pugh class A patients with single 
small HCC nodules < 2 cm, although surgical resection is the 
standard treatment for such tumors (82). Some researchers 
assert local therapies should be the primary treatments 
for these tumors because of the favorable tumor response; 
however, this remains controversial (247). Local therapies 
are less effective for larger tumors, but efforts to improve 
them are being made. Contraindications for local therapies 
include corrected platelet count < 50 x 103/mm3 and low 
prothrombin time (≤ 50%).
Radiofrequency Ablation
Radiofrequency ablation (RFA) is currently the most 
widely used ablation technique for the treatment of HCC. 
Very fast alternating currents (460 to 500 kHz) flow in the 
vicinity of radiofrequency electrodes, inducing internal 
friction among molecules. The internal heat generated by 
the internal friction can evoke tissue necrosis. Heating to 
60°C can cause almost immediate protein denaturation 
and destruction of cell membranes followed by coagulative 
necrosis. Heating to 45–50°C for ≥ 3 minutes can also 
cause similar necrotic effects.
The main advantage of RFA is that fewer treatment 
sessions are required to achieve complete tumor necrosis. 
For HCC nodules > 2 cm, RFA results in a higher complete 
tumor necrosis rate than PEIT (248-251); most procedures 
were performed via a percutaneous approach, although a 
laparoscopic or open surgical approach may be required 
in some instances. Initial complete tumor necrosis rates 
on imaging studies are reported to exceed 96% and if 
RFA procedures are repeated for residual viable tumors, 
a complete tumor necrosis rate of almost 100% can be 
achieved (250). However, the estimated 3-year local tumor 
progression rate after RFA ranges widely from 0.9% to 
21.4% (247, 252, 253).
Despite these favorable outcomes, RFA has some 
disadvantages. First, the risk of major adverse events 
is usually higher than that with PEIT, particularly when 
the tumors are located near the liver hilum or a major 
abdominal organ such as the large intestine. In addition, 
the heat sink effect may hinder effective transmission of 
heat energy to the tumor in cases in which the tumors are 
adjacent to relatively large intrahepatic vessels (251, 254, 
255). However, the risk of thermal injury to the adjacent 
abdominal organs can be overcome by inducing artificial 
ascites (256). Another major limitation of RFA is that 
HCC nodules < 2 cm may not be visible on conventional 
ultrasonography. However, recent applications of ultrasound 
contrast agents and fusion imaging techniques have 
broadened the indications for RFA to such cases (257, 258).
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The mortality rate due to procedure-related complications 
after RFA is reported to be 0.1–0.5%, and the major 
complication rate after RFA is < 5% (247, 254, 255). 
Major complications include needle tract seeding, 
hemoperitoneum, hemothorax, liver abscess, massive 
infarction of liver parenchyma, intestinal perforation, 
pneumoperitoneum, etc. (253). The long-term survival 
outcomes of HCC patients can vary after RFA with respect 
to tumor size. For Child-Pugh class A cirrhotic patients with 
tumors < 2 cm, the 3- and 5-year overall survival rates after 
RFA are reported to be approximately 90% and 65–70%, 
respectively (247, 252, 253); meanwhile, those for tumors 
2–5 cm are 65–75% and 50%, respectively (252, 253). The 
10-year overall survival rate of Child-Pugh class A patients 
with single HCC < 3 cm is 41.3% (253).
In four RCTs comparing RFA and PEIT for patients with 
HCC (249-251, 259, 260), patients treated with RFA showed 
better local tumor response and overall survival outcomes 
than those treated with PEIT. A meta-analysis of these 
four RCTs also demonstrates that the 3-year overall survival 
rate of RFA is significantly higher than that of PEIT (261). 
Nevertheless, for patients with HCC < 2 cm, there is no 
significant difference in survival outcomes between RFA and 
PEIT. Therefore, further prospective controlled studies are 
required.
As it is difficult to compare observational studies 
evaluating the long-term survival outcomes of RFA and 
surgical resection, it is not adequate to draw a definite 
conclusion regarding the superiority of either treatment. 
Three RCTs have recently been published on this topic. 
There were no significant differences in the survival 
outcomes between the two treatments in one RCT for 
solitary HCC < 5 cm and another RCT for single or double 
HCCs < 4 cm (262, 263). However, the other RCT for HCC 
diagnosed according to the Milan criteria indicates the 
superiority of surgical resection over RFA with respect 
to 3- and 5-year overall survival rates (p < 0.001) (264). 
Nevertheless, such results should be interpreted cautiously, 
as RFA is most effective for tumors < 3 cm. A meta-analysis 
of these three RCTs shows that the complication rate was 
usually higher in the resection group than the RFA group (p 
= 0.002) and that hospitalization duration was significantly 
longer in the resection group than the RFA group (p < 0.001) 
(265). Nevertheless, it is not possible to draw a definite 
conclusion about the overall or disease-free survival rate of 
HCC patients on the basis of a meta-analysis of the three 
RCTs mentioned above, because the indications differed 
substantially among studies (265). In contrast, RFA may 
be unfeasible because of the tumor location in some cases, 
making surgical resection more useful (263). As a strategy 
combining the advantages of these treatment modalities 
for small HCCs, i.e., the lower invasiveness of RFA and 
better curative potential of hepatic resection, primary RFA 
and subsequent resection in cases of failed RFA can be 
considered. A recent decision model analysis shows there 
was no difference in the survival outcomes of patients 
with single HCC smaller than 2 cm between the combined 
strategy and resection monotherapy (266).
For intermediate-sized HCCs (i.e., 3–5 cm), the local 
recurrence rates after RFA are reported to range from 30% 
to 50% (252), and combined treatment of TACE and RFA can 
be considered for these tumors. The difference in the 3-year 
overall survival rates between combined treatment and RFA 
monotherapy is < 10% for tumors smaller than 3 cm (267, 
268) but is much greater for HCCs 3–5 cm in diameter (268). 
Meta-analyses of RCTs also show similar results (269, 270).
No RCT has compared re-resection and RFA for recurrent 
HCC following hepatic resection. However, a recent 
retrospective analysis shows that the 2- and 5-year overall 
survival rates after re-resection and RFA are 90% vs. 96% 
and 72% vs. 83%, respectively; the differences are not 
statistically significant (271). Another retrospective study 
shows similar results (272). In those studies, baseline liver 
functional status might have been unfavorable in the RFA 
group compared to the surgical group. Consequently, RFA 
appears comparable to re-resection for the treatment of 
recurrent HCC following hepatic resection, although further 
investigation is necessary to confirm this (273).
Percutaneous Ethanol Injection
Percutaneous ethanol injection therapy (PEIT) is widely 
used in the treatment of HCC because it is relatively 
convenient to perform and adverse reactions are infrequent. 
However, PEIT has been largely supplanted by RFA recently, 
mainly because PEIT should be performed repetitively 
in contrast to RFA and it is difficult to obtain complete 
necrosis for tumors larger than 3 cm. PEIT is now usually 
reserved for patients with ≤ 3 nodules ≤ 3 cm in diameter.
As a special consideration, PEIT can be performed to 
treat perivascular tumors to reduce the heat sink effect of 
RFA. However, the risk of biliary stricture is not eliminated 
by PEIT if the tumors are located in the liver hilum (274). 
The reported rates of tumor necrosis after PEIT range 
between 66% and 100% (249-251, 259). In particular, 
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the therapeutic efficacy of PEIT largely depends on the 
tumor size; the rate of tumor necrosis decreases with 
increasing tumor size. A rate of tumor necrosis ≥ 90% 
is reported for tumors smaller than 2 cm, but the rate 
decreases to approximately 50% for 3–5-cm tumors. Local 
tumor progression rates after PEIT range between 24% and 
34%, although there is no consensus on the definition of 
local tumor progression (275-277). For Child-Pugh class 
A patients with solitary tumors smaller than 2 cm, the 3- 
and 5-year overall survival rates are 70–80% and ≥ 50%, 
respectively. For tumors 2–3 cm in diameter, the 3-year 
overall survival rate ranges from 47% to 64% (249, 259).
For cirrhotic patients with Child-Pugh class A or B and 
a solitary tumor smaller than 3 cm, several comparative 
studies show no definite differences in the survival 
outcomes between PEIT and surgical resection (278, 
279). In particular, an RCT comparing PEIT and surgical 
resection targeting 76 patients who had one or two HCC 
nodules ≤ 3 cm reports no difference in the survival rates 
or local recurrence rates between treatment groups (279). 
However, it is very difficult to reach a definite conclusion 
based on a single RCT. Furthermore, the sample size of that 
RCT was calculated on the basis of the tumor recurrence 
rate and not the survival rate. The 5-year survival rates 
differed greatly–46% and 81.8% in the PEIT and resection 
groups, respectively–even though there was no significant 
difference in the overall survival rates of the two 
treatments. Therefore, additional well-designed prospective 
controlled studies are necessary to reach a definite 
conclusion.
Other Locoregional Therapies 
Other local therapies are currently under investigation, 
including microwave ablation, cryoablation, high-intensity 
focused ultrasound, laser ablation, and holmium injection 
therapy among others. An important advantage of 
microwave ablation over RFA is that treatment efficacy is 
less affected by vessels located near the tumor. In addition, 
effective ablation can be expected even for tissues with low 
electrical conductivity, and the simultaneous application 
of multiple electrodes is technically feasible with this 
technique (280, 281). Despite its potential advantages, no 
RCT has compared microwave ablation and RFA with respect 
to clinical usefulness. 
Furthermore, no RCTs have evaluated the other ablation 
techniques mentioned above; even single-arm studies do 
not demonstrate any additional benefits over RFA with 
respect to response or survival outcomes. Therefore, clinical 
indications for these various ablation techniques are 
currently uncertain.
Recommendations (Table 2)
1) RFA provides survival comparable to that of resection 
in patients with single-nodular HCCs ≤ 3 cm in diameter 
(A2).
2) RFA is superior to PEIT in terms of anticancer effect 
and survival (A1). For HCCs ≤ 2 cm in diameter, PEIT can be 
considered if RFA is unfeasible, because the outcomes of 
both modalities are similar (A2).
3) Survival outcomes can be improved by combining TACE 
and RFA compared to RFA alone in patients with tumors 3–5 
cm in diameter if resection is unfeasible (A2).
TACE and Other Transarterial Therapies
Most HCC patients are unresectable at the time of 
diagnosis because of portal hypertension, poor liver 
functional status, multiplicity of tumors, portal vein tumor 
invasion, inability to secure sufficient resection margin 
around the tumors, old age, and severe comorbidities (282). 
TACE is the most commonly used nonsurgical treatment 
modality for these patients; meanwhile, tumor necrosis 
can be achieved by the combined effects of antitumor 
chemotherapy and selective ischemia of tumor tissue 
(13, 282, 283). TACE is the most widely practiced primary 
treatment modality for HCC in Asia and North America 
(284). TACE can be classified as conventional TACE using 
lipiodol and drug-eluting bead TACE (debTACE) (285, 286). 
It is important to note that TACE should be distinguished 
from transarterial embolization, which uses only embolic 
material, and hepatic arterial infusion chemotherapy (HAIC), 
which uses only antitumor chemotherapeutic agents (287, 
288).
Conventional TACE
The TACE procedure involves mixing chemotherapeutic 
agents such as doxorubin, cisplatin, and mitomycin with 
iodized oil and injecting the mixture into the feeding artery 
as an emulsion. This is followed by arterial embolization 
using gelatin sponge particles, polyvinyl alcohol particles, 
or microspheres, which induce selective tumor ischemia. 
The most important technique for maximizing the antitumor 
effect and minimizing liver toxicity when performing TACE 
is to superselect the feeding arteries of tumors as distal as 
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possible (289). Regarding the repetition strategy of TACE, 
on-demand repetitions to treat the residual or recurrent 
tumors can minimize the incidence of procedure-related 
liver toxicity, which is therefore preferable to on-schedule 
regular repetitions every 1–2 months. 
Several RCTs and meta-analyses confirm compared to 
supportive treatments, TACE results in more favorable tumor 
response, time to progression, and survival outcomes in 
patients with unresectable HCC (77, 290, 291). A recent 
prospective cohort study by the Japanese Liver Cancer 
Study Group reports that the 1-, 3-, 5-, and 7-year survival 
rates of 8510 patients who underwent TACE were 82%, 
47%, 26%, and 16%, respectively; for tumors larger than 
5 cm, the 1-, 3-, and 5-year survival rates were 63%, 
30%, and 16%, respectively (292). In a recent prospective 
multicenter study performed in 27 Japanese and South 
Korean centers, the complete or partial remission rate 
according to the modified Response Evaluation Criteria in 
Solid Tumors (mRECIST) criteria was 73% and the 2-year 
overall survival rate was 75%; these figures are higher 
than those previously reported in the literature (293). In 
that study, grade 3–4 severe toxicities after TACE included 
elevated serum alanine aminotransferase level in 36% 
of patients, thrombocytopenia in 12%, and abdominal 
pain in 4%, while mild fever occurred in 57%. In another 
retrospective analysis, postembolization fever > 38.0°C 
occurred after TACE in 20% of patients; it occurred more 
frequently in patients with tumors > 5 cm and was a poor 
prognostic factor for survival (294). Even though TACE 
can be performed safely in general, severe complications 
such as irreversible hepatic failure occur in 3% of patients 
and postembolization syndrome, which is characterized by 
transient fever and abdominal pain, occurs more frequently, 
affecting 60–80% of patients (295). The best tumor 
response and the lowest complication rates after TACE can 
be expected for patients with favorable performance status, 
with nodular HCCs, and without traces of vascular invasion. 
Future RCTs should evaluate the survival benefits of TACE 
for patients with unfavorable prognostic factors such as 
poor performance status, major portal vein tumor invasion, 
Child-Pugh class C, and extrahepatic metastasis.
Local tumor response after TACE can vary substantially 
according to the size and number of tumors as well as 
patterns of tumor growth, such as tumor encapsulation and 
vascular invasion. The complete remission rate is quite low 
for large or multiple tumors despite multiple TACE sessions. 
However, in cases with small tumors, complete tumor 
necrosis can be obtained in more than 50% of cases after 
superselective TACE (296). For patients with Child-Pugh 
class A and surgically resectable HCC < 4 cm, the 5-year 
overall survival rate after subsegmental TACE is reported to 
exceed 50% (289, 292). A prospective cohort study from 
Korea comparing surgical resection after primary TACE with 
TACE monotherapy published a decade ago reports that 
the survival rates were similar between the two treatment 
groups in cases in stage T3. In addition, the survival rate of 
the TACE group in stage T1 and T2 cases was similar to that 
of the surgical resection group if iodized oil was compactly 
retained within the tumor (297). In a recent prospective 
cohort study on BCLC stage A patients for whom resection 
or ablation could not be performed, the 1-month complete 
remission rate according to the mRECIST criteria were 67% 
and the 3-year overall survival rate was 80% (298). In 
another recent retrospective study comparing resection, 
RFA, and TACE as initial treatments for single small HCC < 3 
cm in diameter, the unadjusted 5-year overall survival rate 
of the TACE group was the lowest at 74.2%. However, after 
adjusting for liver functional status, thrombocytopenia, 
varix, etc., the differences in the survival outcomes among 
the groups lost statistical significance (299). Taking the 
potential selection bias of the abovementioned studies into 
account, TACE can be considered an alternative treatment 
with curative intent if a patient rejects surgical treatment, 
is high risk for surgery, or is contraindicated for RFA.
Portal vein tumor invasion occurs in approximately 30% 
of HCC patients in Korea (13). According to the AASLD 
practice guidelines, systemic chemotherapy with sorafenib 
is the standard primary treatment for HCC invading the 
portal vein (57). However, in practice, this recommendation 
is not routinely followed by physicians, because the 
expected survival benefits are modest (284). Therefore, 
further investigations of effective alternative treatments 
are required. When TACE is performed for HCC patients with 
good hepatic functions but portal vein tumor invasion, 
the risk of hepatic functional deterioration after TACE is 
reported to be acceptably low (300-302). The 1- and 3-year 
overall survival rates of such patients after repeated TACE 
range from 25–35% and 9–10%, respectively (292, 303, 
304). In a prospective study targeting HCCs invading the 
major portal vein, the median survival period of the TACE-
treated group (5.0 to 5.1 months) was 2 to 2.5 months 
longer than those of the supportively treated group; 
however, the difference was not statistically significant 
probably because of the small number of patients included 
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(291, 302). However, a recent study from Korea reports 
that the median survival rate of TACE-treated HCC invading 
the major portal vein is 22 to 30 months for a subgroup of 
patients with nodular tumor growth or limited tumor extent 
(302, 303). A recent prospective nonrandomized study 
on unresectable HCC patients with portal vein invasion 
shows more favorable survival outcomes for the TACE-
treated group than the supportive treatment group (304). 
However, the lack of randomization in that study limits the 
validity of this finding. Therefore, additional well-designed 
RCTs are required to confirm the survival benefits of TACE 
over supportive treatment in HCC patients with portal vein 
invasion. Future investigations are also required to compare 
the clinical effectiveness of TACE monotherapy with other 
monotherapies (i.e., radiation therapy, systemic sorafenib, 
HAIC, etc.) and combined treatments of those therapies and 
TACE while considering liver functional status, tumor extent, 
and the extent of portal vein invasion.
Drug-Eluting Bead TACE
Drug-eluting beads, which are microspheres loaded with 
high-dose doxorubicin, represent a newly developed embolic 
agent for tumor feeders. The major theoretical advantage 
of debTACE is the higher intratumor drug concentration and 
lower serum drug concentration due to the slow release of 
doxorubicin from the microspheres after embolization of the 
tumor feeders. In prospective clinical trials, liver toxicities 
and systemic adverse effects occur less frequently after 
debTACE than conventional TACE (305, 306). In contrast, 
a phase II RCT on 212 HCC patients demonstrates no 
additional benefit of debTACE over conventional TACE with 
respect to 6-month complete or partial remission rate (305). 
However, subgroup analyses show that debTACE was superior 
to conventional TACE in patients with Child-Pugh class B, 
ECOG performance status 1, bilobar disease, or recurrent 
HCCs (305). In another RCT, there was no significant 
difference between the two treatments with respect to 
tumor response, time to progression, or survival period 
(307). The 5-year overall survival rates of HCC patients after 
debTACE and conventional TACE were 38.3% and 22.5%, 
respectively (308, 309).
When debTACE is performed by experienced interventional 
radiologists, postembolization syndrome or systemic adverse 
effects occur less frequently (306, 310). However, there is a 
lack of evidence confirming the long-term survival benefits 
of debTACE compared to conventional TACE, thus warranting 
further phase III RCTs.
Transarterial Radioembolization
Transarterial radioembolization (TACE) involves the 
injection of implantable radioactive microspheres into 
tumor-feeding arteries in order to expose the tumor to 
highly concentrated radiation while protecting the normal 
parenchyma. 90Y is the most commonly used radioisotope 
and emits high-energy and pure β-rays with a half-life of 
64.2 hours, and mean and maximum tissue penetration of 
2.5 and 11 mm, respectively. The microspheres available for 
90Y infusion are about 35 μm in diameter and are made of 
resin or glass. The small size of the injected microspheres 
and their concentration at the hypervascular HCC minimize 
the embolic effect on surrounding tissue. Preprocedural 
angiography and 99mTc-labeled macroaggregated albumin 
scan are required to decide on the treatment site, determine 
the radiation dose, and detect and calculate the degree of 
shunting to the lungs and any other extrahepatic organs.
In a prospective single-arm phase II study of 52 patients 
with intermediate or advanced HCC treated with TARE, the 
objective tumor response rate (i.e., complete or partial 
remission rate) was 40.4%, and the median survival period 
was 15 months (311). In another large retrospective cohort 
study, the median survival periods of patients with and 
without portal vein invasion were 10 and 15.3 months, 
respectively; the difference was statistically significant. 
The median survival periods of patients with Child-Pugh 
class A and B were 17.2 and 7.7 months, respectively; the 
difference was also statistically significant (312, 313). In a 
recent prospective multicenter study performed in Korea on 
40 HCC patients in BCLC stage B or C, the 3-month tumor 
response rate was 57.5% and the 3-year overall survival rate 
was 75% (314).
The most frequent adverse effect after 90Y TARE is 
transient fatigue. However, postembolization syndrome is 
less likely to occur than in conventional TACE, because the 
embolic effect of 90Y TARE is not as strong. Therefore, 90Y 
TARE can be performed safely for patients with portal vein 
tumor thrombosis. Elevated serum bilirubin levels occur 
in 20% of patients, and the mortality rate within 1 month 
ranges from 0% to 3% (311-313). Severe complications 
such as radiation pneumonitis and gastroduodenal ulcer 
can occur in the event of inadvertent embolization into the 
extrahepatic organs. Therefore, 90Y TARE requires meticulous 
precautions and experience performing radioembolization.
In summary, no RCT has compared 90Y TARE with other 
standard treatments with respect to long-term survival 
outcomes and complication rates. Therefore, it is difficult to 
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suggest indications for 90Y TARE in HCC patients. However, 
the incidence of postembolization syndrome and systemic 
adverse effects with 90Y TARE are relative low, and the tumor 
response rates are similar to those of conventional TACE. 
Accordingly, a phase III RCT is required to determine the 
indications, cost-effectiveness, and survival outcomes for 
this new type of treatment.
Recommendations (Table 2)
1) TACE is recommended for patients with good 
performance status without major vascular invasion or 
extrahepatic spread who are ineligible for surgical resection, 
LT, RFA, or PEIT (A1).
2) TACE should be performed through tumor-feeding 
vessels using selective/superselective techniques to 
maximize antitumor activity and minimize hepatic damage 
(B1).
3) Chemoembolization using drug-eluting beads results 
in less systemic adverse events and has similar therapeutic 
efficacy compared with conventional TACE (B2).
4) In case of portal vein invasion, TACE can be considered 
for patients with localized tumors and well-preserved liver 
function (B2).
External-Beam Radiation Therapy
External-beam radiation therapy (EBRT) for the treatment 
of HCC is commonly used for lesions that are surgically 
unresectable and not amendable with other local modalities. 
Child-Pugh class A or upper B are criteria for EBRT. The 
reported overall response rates and median survival after 
EBRT are 40–90% and 10–25 months, respectively (315). 
EBRT requires computerized radiation therapy planning by 
CT, and the liver volume receiving ≥ 30 Gy must be limited 
to ≤ 60% of the total liver volume in three-dimensional 
radiotherapy planning-based dose-volume analysis (316). 
For hypofractionated EBRT consisting of ≤ 10 fractions, the 
normal liver volume receiving < 15 Gy must be ≥ 700 mL 
(317) and the dose to the normal liver volume excluding 
the tumor must be limited to ≤ 28 Gy (corrected to 2 Gy per 
fraction-equivalent dose) (318).
External-beam radiation therapy (EBRT) can be used for 
patients with HCC who are unsuitable for surgical resection, 
LT, RFA, PEIT, or TACE. In most centers, hypofractionated 
radiotherapy including stereotactic ablative radiation 
therapy is used to treat patients with Child-Pugh A or 
superb B liver function and adequate normal liver volume; 
the 2-year local control and survival rates are reported to 
range from 70% to 100% and 50% to 75%, respectively 
(319-325). In particular, stereotactic ablative radiation 
therapy for the treatment of ≤ 3 lesions and lesions with 
a cumulative diameter ≤ 6 cm results in local control rates 
exceeding 90% (319, 323-325). Proton therapy for HCC 
results in a 2-year local control rate from 75% to 96% and 
a 5-year survival rate from 23% to 44% (199, 326-329).
An advantage of EBRT is that it can be performed safely 
regardless of the presence of portal vein invasion by the 
tumor (330-344). One study reports that when EBRT was 
used for patients unsuitable for TACE owing to severe tumor-
induced arteriovenous shunts, 20% of these patients were 
able to undergo TACE successfully after radiation therapy-
induced vascular occlusion (345). A meta-analysis reports 
that the use of TACE in combination with EBRT improves 
the 3-year survival rate by 10–28% compared to TACE 
monotherapy (346). Meanwhile, the results of controlled 
studies comparing combination treatments are anticipated. 
Moreover, the addition of EBRT for HCC after incomplete 
TACE is reported to result in a complete response (CR) rate 
of 20.9% (347). In a Korean multicenter retrospective 
cohort analysis, 78.4% of patients received TACE before 
receiving EBRT (348). Another recent study shows that 
TACE combined with EBRT for resectable HCC with portal 
vein invasion resulted in a superior median survival of 
12.3 months versus 10.0 months for the surgical group 
(349). Furthermore, combined treatment for HCC patients 
with inferior vena cava invasion also resulted in a superior 
median survival period of 11.7 months in comparison with 
the historical cohort who received TACE alone (350). The 
sequential combination of EBRT 2 weeks after TACE may 
be complicated by liver dysfunction; however, Common 
Terminology Criteria of Adverse Events grade ≥ 3 liver 
dysfunction is reported in only 2.5% of all patients (351).
In one study, regional chemotherapy with 5-fluorouracil 
and cisplatin combined with EBRT for locally advanced HCC 
resulted in a 3-year survival rate of 24.1% and a median 
survival period of 13.1 months (352). The same institution 
reports a median progression-free survival of 4.5 months 
and overall survival of 9.8 months after TACE followed by 
EBRT and concurrent intra-arterial 5-fluorouracil for locally 
advanced HCC with portal vein invasion and intrahepatic 
metastases (353). In another study, the addition of EBRT 
to intra-arterial 5-fluorouracil and subcutaneous interferon 
treatment for 40 patients with advanced HCC and portal 
vein invasion significantly improved the time to progression 
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from 4.0 to 6.9 months and the median survival from 9.1 
to 12.0 months (354). EBRT can also be considered a local 
neoadjuvant treatment for large HCCs with the aim of 
improving resectability. Accordingly, it has been reported 
that surgery can be performed safely post-EBRT, resulting 
in an effective response to neoadjuvant radiotherapy (355). 
In addition, EBRT can be considered a bridging treatment 
for patients awaiting LT (199, 200, 319). Nevertheless, a 
controlled prospective comparative study is required to 
establish the role of EBRT as a new adjuvant treatment. 
EBRT can also be used as a second-line treatment for 
recurrent HCC after various nonsurgical treatments including 
TACE (348, 356, 357). 
External-beam radiation therapy is also effective for 
relieving symptoms such as cancer pain (315, 358). In 
patients with jaundice presenting with biliary obstructions 
due to the progression of HCC, EBRT has been demonstrated 
to successfully reduce tumor size and relieve symptoms; 
accordingly, EBRT is also expected to improve the 
survival in these patients (359, 360). In HCC patients 
with abdominal lymph node metastases, EBRT results 
in response rates of approximately 80% (361-364) with 
improved median survival time (365). In HCC patients with 
symptomatic bone metastases, EBRT is reported to relieve 
pain in 75–99% of patients (366-370) as well as symptoms 
in patients with brain metastases from HCC (371). Moreover, 
in a previous study, EBRT doses from 30 to 50.7 Gy for 
spinal cord compression from vertebral metastases resulted 
in ambulatory rates of 85% and 63% at 3 and 6 months, 
respectively (372). In two other studies, EBRT for lung 
metastases resulted in response rates from 60% to 70% 
while symptom relief was observed in 90% of symptomatic 
patients (361, 373).
Recommendations (Table 2)
1) EBRT can be performed in HCC patients if liver 
functions are Child-Pugh class A or superb B and the 
irradiated total liver volume receiving ≥ 30 Gy is ≤ 60% (B1). 
2) EBRT can be considered for HCC patients ineligible for 
surgical resection, LT, RFA, PEIT, or TACE (C1).
3) EBRT can be considered for HCC patients who show 
incomplete response to TACE when the dose-volume criteria 
in Recommendation 1 are met (B2).
4) EBRT can be considered for HCC patients with 
portal vein invasion when the dose-volume criteria in 
Recommendation 1 are met (C1).
5) EBRT is performed to alleviate symptoms caused by 
primary HCC or its metastases (B1).
Systemic Therapies
Sorafenib
Sorafenib is a multi-tyrosine kinase inhibitor targeting 
vascular endothelial growth factor receptor 2, platelet-
derived growth factor receptor, Raf-1, and c-kit. Sorafenib 
was the first approved molecular targeted agent for the 
treatment of HCC. In the SHARP study, a global phase III 
trial, the median survival of HCC patients with portal vein 
tumor invasion or extrahepatic metastasis treated with 
sorafenib was 10.7 months, which was significantly longer 
than 7.9 months in patients who received placebo (HR, 
0.69; 95% CI, 0.55 to 0.87; p = 0.00058) (374). The time 
to progression in the sorafenib group was 5.5 months, 
which was also significantly longer than 2.8 months in the 
control group (374). In an Asia-Pacific phase III trial that 
included Korean patients with unresectable HCC, patients 
who received sorafenib had a significantly longer median 
survival (6.5 months) than that of the control group (4.2 
months; HR, 0.68; 95% CI, 0.50 to 0.93; p = 0.014) (375). 
The median survival of patients treated with sorafenib 
was consistently reported to be approximately 10 months 
in the following 3 randomized controlled phase III trials 
testing novel molecular targeted agent in which sorafenib 
treatment was the control group (376-378). On the basis 
of the results of clinical trials, sorafenib is currently the 
only molecular targeted agent proven to prolong survival in 
advanced HCC patients.
The abovementioned two phase III trials for sorafenib 
(i.e., the SHARP and Asia-Pacific trials) recruited HCC 
patients with Child-Pugh class A and ECOG performance 
status 0–2. In clinical practice, the safety and efficacy 
of sorafenib are reported to be comparable between 
Child-Pugh class A and B patients (379-382); however, 
the prognosis is reported to differ with respect to the 
presence of ascites and Child-Pugh score (383). Thus, 
although sorafenib can be used cautiously in patients 
with decreased liver function, more controlled studies 
are necessary. The most common adverse event related 
to sorafenib treatment is hand-foot syndrome reaction 
(HFSR), followed by fatigue, skin rash, anorexia, weight 
loss, hypertension, and alopecia. As HFSR tends to be 
decreasing sptontaneously after 3 months of treatment, it 
is important to continue therapy through patient education 
and proper management; for example, creams containing 
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urea may be helpful for preventing dryness of the hands 
and feet. Furthermore, it is recommended to remove thick 
calluses, wear comfortable shoes with cushioning, avoid 
hot water, and take analgesics if necessary (384). Sorafenib 
is primarily used in advanced HCC patients with vascular 
invasion (i.e., the portal vein, hepatic vein, or inferior 
vena cava) or extrahepatic metastasis. It can also be used 
in HCC patients in whom locoregional therapies have failed 
or are not indicated. Although there is no clear definition 
of TACE failure or refractoriness, if HCC progresses and the 
tumor stage advances despite repeated applications of TACE 
(i.e., 3 times within 6 months) for residual or recurrent 
tumors after the initial TACE, sorafenib might be indicated 
on the basis of the concept of TACE failure or refractoriness 
(385-387). Regarding combination therapy with TACE and 
sorafenib in intermediate-stage HCC, a single-center phase 
II study shows longer survival and time to progression in 
combination therapy than a historic control group treated 
with TACE monotherapy (388); while another phase II study, 
the SPACE trial, does not show the beneficial outcomes of 
combination therapy (389); the former has the limitation 
of being a single-arm study, while the latter has drawbacks 
of study design, specifically not “on-demand” TACE but 
“scheduled” TACE and an endpoint of overall survival in 
patients with intermediate-stage HCC, who are expected 
to have favorable long-term prognosis. On the basis of the 
proven safety of combination therapies in both of these 
trials, there is an ongoing phase III trial of combination 
therapy with TACE and sorafenib in advanced HCC. 
Recommendations (Table 2)
1) Sorafenib is indicated for HCC patients with very 
well-preserved liver function (i.e., Child-Pugh class A), 
good performance status, and regional lymph node or 
extrahepatic spread or patients with tumor progression on 
other therapies (A1).
2) Sorafenib is recommended for HCC patients with very 
well-preserved liver function (i.e., Child-Pugh class A), and 
good performance status, and vascular invasion (A2).
3) Sorafenib is considered for HCC patients with preserved 
liver function (i.e., Child-Pugh class superb B) and good 
performance status if the above conditions (1 and 2) are 
satisfied (B1).
Cytotoxic Chemotherapy
Sorafenib is recommended as a first-line systemic agent; 
however, despite several clinical trials, no second-line agent 
is proven to be effective in cases in which sorafenib fails or 
intolerance. Cytotoxic chemotherapy can be considered in 
cases of HCC progression on sorafenib or drug intolerance 
(390-392). Most cytotoxic chemotherapeutics have shown 
poor response and no survival benefit through RCTs. Even 
though some agents result in a relatively good antitumor 
response, it is unrealistic to perform a multicenter 
prospective RCT evaluating efficacy and safety because of 
lack of study funding/sponsership. 
Despite the widespread use of doxorubicin, the response 
rate is less than 20% (393-395). Satisfactory results have 
not been obtained with single agents such as 5-fluorouracil 
(396), gemcitabine (397, 398), oxaliplatin (399), 
capecitabine (400), and irinotecan (401). In addition, 
octreotide (402, 403), interferon (404), and tamoxifen (405) 
have not shown any survival benefit for HCC.
Several combination regimens have been tried because 
of the modest efficacy of monotherapy. The PIAF regimen 
(cisplatin/interferon α-2b/doxorubicin/fluorouracil) shows 
better objective response rates (20.9% vs. 10.5%; p = 0.058) 
and median overall survival (8.67 months vs. 6.83 months; 
RR, 0.97; p = 0.830), although the difference failed to 
reach statistical significance. Meanwhile, hematologic 
toxicities were significantly more frequent in PIAF group 
(406). Another combination regimen, FOLFOX (oxaliplatin/
fluorouracil/leucovorin) was compared with doxorubicin 
monotherapy. Patients receiving FOLFOX had significantly 
better progression-free survival (2.93 months vs. 1.77 
months; p < 0.01) and disease control rate (52.17% vs. 
31.55%; p < 0.001) but a nonsignificant trend toward 
better survival (6.4 months vs. 4.97 months; p = 0.07) 
(407). Some results of cisplatin-containing regimens (e.g., 
in combination with doxorubicin (408), capecitabine (409, 
410), or 5-fluorouracil (411)) or oxaliplatin-containing 
regimens (e.g., in combination with gemcitabine (412) or 
capecitabine (413)) for HCC have been reported, but the 
benefits of these regimens compared to monotherapy are 
still lacking.
Most patients with HCC are accompanied by chronic liver 
disease or liver cirrhosis, which can alter the metabolism 
of chemotherapeutics and increase their toxicity (414). 
Therefore, systemic chemotherapy should be reserved for 
patients with good performance status and liver function. 
In addition, great care is required to maintain the quality 
of life of patients receiving chemotherapeutics.
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Hepatic Arterial Infusion Chemotherapy
Hepatic Arterial Infusion Chemotherapy (HAIC) can 
directly deliver high concentrations of chemotherapeutic 
agents via the hepatic artery with low systemic toxicities. 
HAIC is usually performed for HCC with portal vein invasion 
and can be considered for TACE-refractory cases. Recent 
reports demonstrate that HAIC can also be tried for 
sorafenib-refractory or intolerant HCCs, although further 
studies are warranted (415, 416). The most widely used 
agent in HAIC is 5-fluorouracil, which is either administered 
alone or with cisplatin, showing response rates from 3.8% 
to 38.5% and median survival from 5 to 19.5 months 
(417-420). HAIC can be administered in combination with 
systemic interferon (421, 422). The implantable device 
required for HAIC can sometimes cause complications such 
as infection and occlusion. Nevertheless, further studies 
are warranted, because there is insufficient evidence 
demonstrating that HAIC improves survival compared to 
systemic chemotherapy or best supportive care.
Recommendations (Table 2)
1) Cytotoxic chemotherapy can be considered for HCC 
patients with advanced tumors who have well-preserved 
liver function and good performance status in whom 
sorafenib therapy has failed (C1).
Adjuvant Therapy
Adjuvant therapy usually refers to an additional treatment 
after definitive or curative therapy to prevent recurrence. 
As there recurrence rate 5 years after curative resection for 
HCC is very high at 70% (see “Liver Resection” section) 
(142, 423, 424), an effective adjuvant therapy is urgently 
required. There is currently no proven modality (58); neither 
sorafenib nor cytotoxic chemotherapy is recommended as 
an adjuvant therapy. Furthermore, there is no evidence that 
TACE prevents HCC recurrence after curative resection (425). 
Although one study reports that 131I infusion via 
the hepatic artery after curative resection reduces the 
recurrence of HCC, no validation study was performed (426, 
427). Thus, this radionuclide therapy is not recommended 
at present. A study of activated immune cells derived from 
patients shows a 15% decrease in the 3-year recurrence 
rate compared to that of the control group (428). However, 
there has been no reliable study to corroborate this.
Transarterial chemoembolization can result in the 
downstaging of HCC, enabling curative resection. Even for 
resectable HCC, TACE can be applied prior to resection as 
a neoadjuvant therapy. However, there is no evidence that 
TACE followed by resection increases disease-free survival 
compared with resection only in resectable HCC (429).
Recommendations (Table 2)
1) Adjuvant TACE, sorafenib, and cytotoxic chemotherapy 
are not recommended for HCC patients treated with curative 
resection (B1).
Preemptive Antiviral Treatment
HBV Carriers
The rate of HBV reactivation in HCC patients after 
cytotoxic chemotherapy varies widely from 30% to 60% 
(430, 431), and the subsequent mortality rate is reported 
to be approximately 30% of all deaths resulting from HBV 
reactivation. HBV reactivation with concomitant elevation 
of serum HBV DNA level or abnormality of biochemical liver 
function is observed in 20–50% of total HBV carriers who 
receive immunosuppressants or cytotoxic chemotherapy 
for the treatment of malignancies other than HCC (e.g., 
breast cancer, hematologic malignancies, and other solid 
cancers) (430, 432-435). Therefore, the test for hepatitis 
B surface antigen (HBsAg) must be performed in patients 
at high risk for HBV infection prior to immunosuppressive 
therapy or cytotoxic chemotherapy (436). Antiviral drugs 
should be preemptively administered in HBV carriers at the 
onset of the cytotoxic chemotherapy or immunosuppressant 
administration and must be continued for at least 6 months. 
Although further research is required to clarify the adequate 
serum HBV DNA level, recurrence is more likely after the 
discontinuation of antiviral drugs in patients with high 
HBV DNA levels prior to cytotoxic chemotherapy. Therefore, 
in patients with HBV DNA levels > 2000 IU/mL prior to 
cytotoxic chemotherapy, continuation of antiviral treatment 
should be considered until the treatment goal of chronic 
hepatitis B is reached (436). Most studies on preemptive 
antiviral treatment are limited to lamivudine, but other 
recently developed antiviral drugs can be used. In cases of 
lamivudine resistance, antiviral drugs should be replaced 
according to the treatment guidelines for resistance (437, 
438). In cases in which antiviral therapy is expected 
to continue for more than 12 months in particular, the 
antiviral drug with the minimum resistance profile should 
be selected (439, 440). Interferon is not recommended as 
a preemptive treatment because of the risk of bone marrow 
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suppression and transient aggravation of hepatitis. In the 
HBsAg-negative, anti-HBc–positive, and anti-HBs–positive 
patients, HBV reactivation can develop very rarely, and 
there is little evidence to recommend uniform preemptive 
treatment owing to a lack of research (436).
Comparatively many studies have evaluated HBV 
reactivation during TACE for the treatment of HCC; HBV 
reactivation is reported to occur in 4–40% of patients (430, 
441-445). According to a study comparing preemptive 
lamivudine treatment to a nonadministered control group 
during TACE (444), significant differences were observed 
with respect to HBV reactivation (2.8% and 40.5%) as 
well as the consequent occurrence of hepatitis (2.8% and 
19.7%) and liver failure (0% and 8.1%). Hence, preemptive 
antiviral treatment can be considered for HBV-positive 
HCC patients undergoing TACE. However, differences in 
chemotherapeutic agents, and treatment interval and 
frequency may have resulted in discordant HBV reactivation 
rates (444-446). Therefore, additional research is required 
to determine the serum HBV DNA levels and biochemical 
liver function test levels that require preemptive antiviral 
treatment.
Hepatitis B virus reactivation rates after HAIC for HCC 
(24–67%) are reported to be higher than those after TACE 
possibly because of the higher dose of chemotherapeutic 
agents, as HAIC is carried out in shorter intervals (431, 
447, 448). However, more research is needed to support the 
claim that HAIC has a higher reactivation rate than TACE, as 
only a few studies with a limited number of subjects have 
been reported and no comparative study with TACE has been 
performed.
Following the surgical resection of HCC, HBV reactivation 
with concomitant elevation in the HBV DNA level or 
abnormal biochemical liver function test is observed in 14–
32% of patients (449). In a prospective study comparing 
preemptive telbivudine administration to a nonadministered 
control group from the day of resection, the HBV 
reactivation rates were 2.5% and 31.8%, respectively. 
While 57.1% of the control group showed HBV reactivation 
within 1 week following surgical resection, only 2.5% of 
the telbivudine-administered group showed reactivation 
within 4 weeks (439). The authors of that study recommend 
preemptive antiviral treatment before the surgical resection 
of HCC; however, that study involved only few patients 
at a single institution in China. Therefore, a large-scale 
multicenter study should be performed to determine a 
universal preemptive antiviral treatment before the surgical 
resection of HCC.
A study comparing preemptive lamivudine administration 
and a nonadministered control group following radiotherapy 
for HCC reports the HBV reactivation rates to be 0% and 
21.8%, respectively; meanwhile, alanine transaminase 
elevation occurred in 2.3% and 12.5% of patients, 
respectively (450). Another recent report suggests 
concurrent TACE and external radiotherapy may double 
the HBV reactivation rate compared to TACE alone (446). 
However, it is difficult to recommend preemptive antiviral 
treatment before external radiotherapy for HCC because of 
the lack of controlled prospective studies.
There are limited studies regarding HBV reactivation 
from PEIT or RFA; nonetheless, the HBV reactivation 
rates for these therapies are reported to be 0% and 
5.6–9.1%, respectively (451, 452). Meanwhile, no HBV 
reactivation was observed after sorafenib administration in 
a retrospective study (380). Regardless, more observations 
and research are required.
HCV Carriers
Regarding HCV-related HCC, there are almost no reported 
cases of HCV reactivation or aggravation of hepatitis after 
HCC treatment. In a recent retrospective study on hepatitis 
virus reactivation comparing HCV- and HBV-related HCC 
after TACE, the rates of HCV and HBV reactivation, hepatitis, 
and liver failure were 26.5% and 32.5%, 10.2% and 34.8%, 
and 0% and 10.9%, respectively (453). No significant 
difference was observed between the HCV and HBV groups 
with respect to the reactivation rate, but the development 
of hepatitis and liver failure were significantly lower in 
the HCV-related HCC group. Hepatitis C treatments can 
be considered in patients with active chronic hepatitis C 
and completely eradicated HCC. As interferon and ribavirin 
administration may cause bone marrow suppression 
and transient aggravation of hepatitis, they are not 
recommended as preemptive treatments before cytotoxic 
chemotherapy in HCC patients.
Recommendations (Table 2)
1) Patients should be tested for hepatitis B surface 
antigen before starting cytotoxic chemotherapy or 
immunosuppressive therapy (A1).
2) Preemptive antiviral therapy is recommended for HBV 
carriers undergoing cytotoxic chemotherapy to prevent 
reactivation (A1). Preemptive antiviral therapy is considered 
for HBV infected patients receiving TACE (B1), hepatic 
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arterial infusion chemotherapy (C1), surgical resection (C1), 
or EBRT (C1) to prevent reactivation.
3) Antiviral treatment for HBV reactivation should follow 
the recommendations of the current KASL guidelines (A1). 
Drug Treatment for Cancer Pain in HCC
Pain is one of the most troublesome symptoms in cancer 
patients. The prevalence of pain in cancer patients ranges 
from 45% to 53% (454-456), and early aggressive palliative 
care including pain management could improve survival in 
lung cancer patients (457). A few studies have investigated 
the prevalence of pain in HCC patients, which is reported 
to range from 22% to 66.8% (455, 458, 459). Therefore, 
pain management should be considered an important aspect 
of palliative care for HCC patients. As most HCC patients 
have chronic liver disease and/or liver cirrhosis, their drug 
metabolism may be altered according to the degree of liver 
dysfunction (460). Furthermore, HCC patients receiving 
analgesics may suffer from more frequent and severe side 
effects. However, there is a paucity of studies on pain 
management for patients with HCC and liver disease (461). 
Therefore, drug treatment for cancer pain in HCC patients 
should generally follow the principles of pain management 
for general solid tumors (462-464). However, drug 
selection, dosage, and administration interval might need 
to be adjusted according to the degree of liver function 
impairment.
The universal strategy for cancer pain treatment is based 
on a sequential three-step analgesics ladder approach 
from nonopioids to weak opioids and finally to strong 
opioids according to pain intensity and the efficacy of pain 
control (462-464). The main nonopioid analgesics such as 
acetaminophen and nonsteroidal anti-inflammatory drugs 
(NSAIDs) are indicated for the treatment of mild pain 
(numerical rating scale, 1–3). Meanwhile, weak opioids 
such as codeine, hydrocodone, and tramadol are indicated 
for mild to moderate pain (numerical rating scale, 4–6). 
Finally, strong opioids such as morphine, oxycodone, 
hydromorphone, fentanyl, and their analogues are the 
mainstay of analgesics for treating moderate to severe 
cancer-related pain (numerical rating scale, 7–10).
Acetaminophen is the most common cause of fulminant 
hepatic failure (465, 466), but clinically significant hepatic 
injury is very rare when the dosage is limited to 4 g/day 
(467). Although one case report demonstrates that even 
therapeutic doses of acetaminophen less than 4 g/day in 
alcoholic patients without liver cirrhosis can result in acute 
liver failure (468), other studies show 4 g/day in alcoholic 
patients is not associated with a significant increase in liver 
toxicity (469, 470). Moreover, one study shows a significant 
increase in the liver enzymes of alcoholic patients taking 
acetaminophen 4 g/day (471). In patients with cirrhosis, 
acetaminophen 2–3 g/day is not associated with acute 
hepatic decompensation (472). Even though the half-life 
of oral acetaminophen is twice as long in patients with 
cirrhosis compared to healthy controls (473), significant 
hepatic injury is rare in patients with liver disease and/
or cirrhosis at a dosage of less than 4 g/day (473, 474). 
Nonetheless, most experts recommend lowering the dosage 
of acetaminophen to 2–3 g/day in patients with liver 
cirrhosis because of the inevitable possibility of altered 
drug metabolism and increased half-life (475, 476).
The unbound drug concentrations of NSAIDs are generally 
elevated in liver disease patients, which can lead to more 
severe side effects and toxicity (477). Indeed, roughly 
10% of total drug-induced hepatotoxicity cases are related 
to NSAIDs (478), and NSAID-induced liver injury is well 
documents (466, 479). Moreover, NSAIDs can cause 
nephrotoxicity (480), gastric ulcer, hemorrhage (481, 482), 
decompensation of liver function, etc. (472).
As the liver is the major site of metabolism for most 
opioids, impaired metabolism and excretion of opioids 
due to underlying liver disease in HCC patients can lead 
to increased side effects. Moreover, opioids are a well-
known major precipitants of hepatic encephalopathy 
(474). Therefore, careful selection, and dosage and interval 
adjustment of drugs are required according to the liver 
metabolism of each opioid (476, 483). Morphine is an 
active analgesic compound by itself, and more than 90% of 
metabolites are excreted renally after glucuronidation in the 
liver. The half-life of morphine is approximately twice as 
long in cirrhotic patients as that in healthy controls (484, 
485). Furthermore, its bioavailability is 4-fold greater in 
patients with HCC (68%) as that in healthy controls (17%) 
(486). As the analgesic effect of codeine is presumed to 
be secondary following its conversion to morphine, serum 
levels are not expected. The ceiling effect of codeine 
may cause side effects before achieving a sufficient 
analgesic effect. Similarly, hydrocodone is metabolized to 
hydromorphone before producing an analgesic effect, which 
results in variable serum levels. Meanwhile, tramadol has 
10-fold less affinity for opioid receptors than codeine and 
exerts its analgesic effect via the peripheral pain pathway, 
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which may result in fewer side effects in patients with 
liver disease. However, its elimination half-life is up to 
3-fold greater in patients with primary liver carcinoma than 
that in controls (487). Oxycodone is converted to various 
metabolites including oxymorphone (an active metabolite), 
which may result in variable serum levels of metabolites and 
an unpredictable analgesic effect. The elimination half-life 
of oxycodone is prolonged, while its clearance is diminished 
with significant ventilation depression in pretransplantation 
liver cirrhosis patients compared to posttransplantation 
patients (488). Hydromorphone is an active analgesic 
compound by itself and is metabolized and excreted 
after glucuronidation. Liver dysfunction does not have a 
relatively substantial effect on hydromorphone; the half-life 
of hydromorphone does not differ significantly in patients 
with moderate hepatic impairment compared to controls 
(489). Although fentanyl is metabolized by cytochrome, its 
metabolism does not yield toxic metabolites, significantly 
alter serum levels in cirrhotic patients (490). Furthermore, 
it is not influenced by renal dysfunction (476, 483).
Recommendations (Table 2)
1) Careful consideration is required for pain management 
with medication in patients with HCC and underlying liver 
disease. The dosage and dosing intervals of analgesics 
should be determined on the basis of liver functions (C1). 
2) In patients with HCC and chronic liver disease, the 
dosage of acetaminophen should be lowered (C1) and 
NSAIDs should be used with caution (B1). 
3) In patients with HCC and chronic liver disease, opioid 
analgesics and their dosage should be selected carefully on 
the basis of drug metabolism and liver function (C1).
Assessment of Tumor Response and 
Posttreatment Follow-up
Tumor Response
The main endpoint in cancer research is overall survival. 
Nonetheless, tumor response and time to progression are 
also considered pivotal for the surrogate assessment of 
efficacy. In oncology, tumor response was initially measured 
according to the 1979 World Health Organization (WHO) 
criteria as follows (491):
1) CR: Complete disappearance of all known disease and 
no new lesions determined by two observations not less 
than 4 weeks apart.
2) Partial response (PR): 50% reduction in total 
tumor load of all measurable lesions determined by two 
observations not less than 4 weeks apart.
3) Progressive disease (PD): 25% increase in the size of 
one or more measurable lesions or the appearance of new 
lesions.
4) Stable disease (SD): Cases not belonging to CR, PR, or 
PD.
However, several problems arose when applying these 
definitions to clinical practice. For example, there were 
discrepancies in the criteria for measuring tumor size 
among researchers. Furthermore, some researchers define PD 
on the basis of the change in the size of one tumor, while 
others define it on the basis of the sum of the changes 
in the sizes of all tumors. Another limitation of the WHO 
criteria is properly reflecting the changes in tumor volume 
determined by recent advanced CT and MRI technologies. 
In order to overcome these problems, the Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria and 
RECIST version 1.1 were developed and released in 2000 
and 2009, respectively. In these criteria, overall responses 
are determined after evaluating the treatment responses for 
all lesions that are targeted or nontargeted (492, 493). The 
criteria used to determine objective tumor responses for 
targeted lesions (or an index lesion) are as follows:
1) CR: Disappearance of all targeted lesions. Any 
pathologic lymph nodes must have reduction in short axis 
to < 10 mm. 
2) PR: At least a 30% decrease in the sum of the 
diameters of target lesions with respect to baseline sum 
diameter.
3) PD: At least a 20% increase in the sum of the diameter 
of the target lesion. In addition to the relative increase of 
20%, the sum must also demonstrate an absolute increase 
of at least 5 mm.
4) SD: Cases not belonging to CR, PR, or PD.
Meanwhile, the criteria for the evaluation of nontargeted 
lesions are as follows (492, 494):
1) CR: Disappearance of all nontargeted lesions and 
normalization of tumor marker levels. All lymph nodes must 
be nonpathologic in size (i.e., < 10 mm short axis).
2) Noncomplete response/nonprogressive disease: 
Persistence of one or more on-target lesions and/or 
maintenance of tumor marker levels above the normal 
limits.
3) PD: Progression of existing nontargeted lesions or 
appearance of new lesions.
However, these criteria were primarily designed to 
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evaluate cytotoxic agents. Therefore, they do not address 
measures of antitumor activity besides tumor shrinkage; 
thus, the best response in these criteria might be SD. 
As acknowledged in the original RECIST publication, 
assessments based solely on changes in tumor size can 
be misleading when applied to other anticancer drugs 
such as molecular targeted therapies or other therapeutic 
interventions (492). Therefore, these determinations may 
be inaccurate. Several clinical studies on HCC demonstrate 
that the RECIST criteria do not mirror the extent of tumor 
necrosis induced by interventional therapies or new 
molecular targeted drugs (374, 495). In theory, viable 
tumor formation should be assessed by CT or MRI studies, 
and tumor viability should be defined according to the 
uptake of contrast agent in the arterial phase of dynamic 
imaging studies. In fact, extensive tumor necrosis, which 
develops after local treatment, may not be paralleled by 
a decrease in lesion diameter (374, 495). To overcome 
these limitations, the EASL developed new criteria for HCC 
treatment response that take into account the degree of 
necrosis (496). Furthermore, mRECIST criteria were first 
proposed by a panel of experts (497, 498); this proposal 
is based on the fact that the diameter of the target 
lesions with viable tumors should guide all assessments. 
Specific modifications to the original criteria regarding 
the assessment of vascular invasion, lymph nodes, ascites, 
pleural effusion, and new lesions are summarized in Table 
7. However, a limitation that should be noted is that the 
assessment of response to treatment based on the mRECIST 
criteria can be influenced by the image quality of CT/MRI 
as well as the subjective decisions of radiologists. Because 
there is no solid evidence indicating which set of criteria 
is superior, the panel of experts recommends determining 
whether a set of criteria outperforms the conventional 
RECIST criteria as well as correlations with pathologic 
studies and outcome prediction.
Recommendations (Table 2)
1) Assessment of response should follow both the RECIST 
and mRECIST criteria (B1).
Follow-up after Complete Response
Follow-up data after CR in HCC are very limited. In 
cases of CR after hepatic resection, transplantation, 
or percutaneous local ablation, follow-up intervals are 
determined on the basis of pretreatment risk factors and 
the treatment-specific risk of recurrence.
 The 5-year recurrence rate following hepatic resection 
is up to 70% and is due to intrahepatic metastases and/or 
de novo carcinogenesis (96, 423, 499, 500). Postoperative 
recurrence is usually classified as early (i.e., < 2 years 
postoperatively) or late (i.e., > 2 years postoperatively) 
(142, 497). Risk factors for recurrence are related to 
the tumor or underlying chronic liver disease. Tumor-
related risk factors for recurrence are associated with 
early recurrence and include tumor size and number, 
degree of differentiation, vascular invasion, serum AFP (if 
elevated preoperatively), insufficient resection margin, and 
nonanatomical resection (142, 146, 499-502). Meanwhile, 
late recurrence risk factors are related to underlying liver 
disease and include elevated serum HBV DNA during the 
perioperative period in cases of chronic hepatitis B (148, 
503-505), and persistent active inflammation and advanced 
degree of fibrosis in cases of chronic hepatitis C (506, 507).
The 5-year survival rate of LT exceeds 70% and the 
recurrence rate is less than 15% in patients meeting 
Milan criteria (163). Major risk factors for recurrence after 
transplantation are tumor size and vascular invasion; 
other risk factors include tumor number, degree of 
differentiation, serum AFP level, and bilobar location 
of tumors (508-510). Recurrence occurs in more than 
90% of patients within 2 years, 35% of which occur in 
the liver if the abovementioned risk factors are present. 
A recent multicenter study from Korea reports that the 
recurrence-free survival was significantly lower in living 
donor than DDLT (511). Thus, follow-up after LDLT should 
be emphasized, especially in countries where most liver 
transplants are cases are from living donors, such as Korea.
Local recurrence rates up to 2 years after treatment are 
higher after RFA (2–18%) or PEIT (11–45%) than after 
surgery, respectively (249-251, 259, 260). The 4-year 
cumulative recurrence rate after RFA for single tumors 
< 3 cm is 57%. Meanwhile, the 3-/5-year cumulative 
recurrence rates after RFA or PEIT for ≤ 3 tumors < 3 cm in 
diameter are 57/72% and 64/77%, respectively (512, 513). 
Incomplete tumor necrosis often occurs after PEIT, and the 
local recurrence rate is up to 43% for large tumors > 3 cm 
(514). RFA for patients with a single nodular tumor < 2 cm 
results in a 5-year survival rate of 70% (247). Improved 
survival is anticipated when CR after retreatment with 
RFA is achieved for local recurrence after RFA. Thus, early 
detection of local recurrence after RFA is of the utmost 
importance (515).
Recurrence usually develops within 2 years after 
496
KLCSG-NCC Korea
Korean J Radiol 16(3), May/Jun 2015 kjronline.org
potentially curative treatments. Because early detection of 
recurrence allows the possibility of reapplication of curative 
treatment modalities, posttreatment monitoring should be 
performed frequently enough to detect recurrence as early 
as possible. However, the ideal monitoring intervals and 
methods require further research. Therefore, we recommend 
follow-up with dynamic enhanced imaging (i.e., CT or MRI) 
or MRI with liver-specific contrast agent every 2–6 months 
for the first 2 years after curative treatment. After 2 years 
without recurrence, follow-up can be performed at less 
Table 7. Assessment of Tumor Response*
RECIST mRECIST
Target lesion response
CR Disappearance of all target lesions
Disappearance of any intratumor arterial 
  enhancement in all target lesions
PR
At least a 30% decrease in the sum of the 
  diameters of target lesions, taking the baseline 
  sum of the diameters of target lesions as a 
  reference
At least a 30% decrease in the sum of the 
  diameters of viable (enhancement in the arterial 
  phase) target lesions, taking the baseline sum of 
  the diameters of target lesions as a reference
SD Any case that does not qualify for either PR or PD Any case that does not qualify for either PR or PD
PD
An increase of at least 20% in the sum of the 
  diameters of target lesions, taking the smallest 
  sum of the diameters of target lesions recorded 
  since treatment started as a reference
An increase of at least 20% in the sum of the 
  diameters of viable (enhancing) target lesions, 
  taking the smallest sum of the diameters of 
  viable (enhancing) target lesions recorded since 
  treatment started as a reference
Nontarget lesions response
CR Disappearance of all nontarget lesions
Disappearance of any intratumor arterial 
  enhancement in all nontarget lesions
IR/SD Persistence of one or more nontarget lesions
Persistence of intratumor arterial enhancement 
  in one or more nontarget lesions
PD
Appearance of one or more new lesions and/or 
  unequivocal progression of existing nontarget 
  lesions
Appearance of one or more new lesions and/or 
  unequivocal progression of existing nontarget 
  lesions
mRECIST Recommendations
Pleural effusion and ascites
Cytopathologic confirmation of the neoplastic nature of any effusion that appears or worsens during 
  treatment is required to declare PD
Porta hepatis lymph node
Lymph nodes detected at the portal hepatitis can be considered malignant if the lymph node short 
  axis is at least 2 cm
Portal vein invasion
Malignant portal vein invasion should be considered a nonmeasurable lesion and thus included in the 
  nontarget lesion group
New lesion
A new lesion can be classified as HCC if its longest diameter is at least 1 cm and the enhancement 
  pattern is typical of HCC. A lesion with an atypical radiological pattern can be diagnosed as HCC by 
  evidence of at least 1-cm interval growth
Overall Response Assessment in mRECIST
Target Lesion Nontarget Lesion New Lesion Overall Response
CR CR No CR
CR IR/SD No PR
PR Non-PD No PR
SD Non-PD No SD
PD Any Yes or no PD
Any PD Yes or no PD
Any Any Yes PD
*Adapted from J Hepatol 2012;56:908-943 (58) and Semin Liver Dis 2010;30:52-60 (498). CR = complete response, HCC = hepatocellular 
carcinoma, IR = incomplete response, mRECIST = modified RECIST, PD = progressive disease, PR = partial response, RECIST = Response 
Evaluation Criteria in Solid Tumors, SD = stable disease
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frequent intervals. In addition, the monitoring interval 
should be individualized on the basis of patient-specific 
risk factors according to tumor biology and underlying liver 
diseases (516, 517).
Recommendations (Table 2)
1) Patients with complete response after treatment should 
be followed up with imaging studies (i.e., dynamic contrast-
enhanced CT/MRI or MRI with liver-specific contrast agents) 
and serum tumor markers every 2–6 months in the first 2 
years; thereafter, patients should be followed by regular 
checkups at individualized intervals (B1).
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Appendix 3. List of Clinical Questions
Internal medicine
1. Could the incidence of HCC be reduced by primary, secondary, or tertiary prevention?
2. How should we determine the high-risk group, imaging tests, roles of tumor markers, and diagnostic criteria?
3. Should we limit exposure to radiation to that necessary to diagnose and treat patients with HCC?
4. What staging system is applicable in Korea?
5. Who can obtain a survival benefit from sorafenib therapy? Is it safe and feasible in patients with hepatic impairment?
6. Does cytotoxic chemotherapy have a role in advanced HCC? Who should be considered for cytotoxic chemotherapy?
7. Does adjuvant therapy have a role after curative treatment for HCC?
8. When can preemptive antiviral therapy for hepatitis B be considered for patients undergoing treatment for HCC?
9. Can preemptive antiviral therapy for hepatitis C be considered for patients undergoing treatment for HCC?
10. How should we address pain management for patients with HCC?
11.  For what kinds of pain medication should we adjust the dose and intervals? What can we adopt as a parameter of  
 liver function in patients with HCC?
12. What criteria can we use to assess response to HCC treatment?
13. When and how should we follow-up patients after curative treatment for HCC?
Surgery
1. Should we consider size of the tumor and patient age when performing liver resection for HCC?
2. Is it applicable to perform the ICG-R15 test, Fibroscan, MRI, or PET to decide on liver resection?
3. How good are the outcomes of liver resection in patients with mild portal hypertension?
4. What is the safe volume of residual liver after liver resection in patients with liver cirrhosis?
5. Is anatomical resection superior to nonanatomical resection?
6. Is it useful to perform preconditioning when performing surgical resection for HCC?
7. Is it useful to perform surgical resection for HCC with bile duct invasion?
8. Is it useful to perform surgical resection for HCC with vascular invasion?
9. Is it useful to perform surgical resection for ruptured HCC?
10. What are the results (i.e., 5-year survival rate, mortality rate, and recurrence rate) of liver resection?
11. Is laparoscopic liver resection comparable to open resection? What are the advantages and indications?
12. When can we recommend liver transplantation as a primary treatment?
13. Do subcentimeter nodules alter the indications for liver transplantation?
14. What tests should be performed to investigate extrahepatic spread prior to liver transplantation?
15.  How can we manage patients with HCC on the waiting list for liver transplantation? Is neoadjuvant therapy effective  
 for them? Does neoadjuvant therapy decrease the withdrawal rate?
16. Can living donor liver transplantation be a substitute for deceased donor liver transplantation?
17. Do the Milan criteria have a role as indications for living donor liver transplantation or salvage transplantation?
18. Is the donor safe when performing living donor liver transplantation?
19. Can salvage transplantation be curative for recurred HCC?
20. Is it safe to perform salvage transplantation for recurred HCC after surgical resection?
21.  What kinds of bridging therapies are available for patients on the transplant waiting list? Do they have a clinical  
 impact?
22.  When do we need to downstage HCC prior to liver transplantation? Can we improve clinical outcomes or broaden  
 indications?
23. How should we treat liver transplant recipients with immunosuppressive or antiviral agents?
24. Should patients receive adjuvant therapy after liver transplantation? Is it useful or necessary?
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Appendix 3. List of Clinical Questions (Continued)
Radiology
1.  Is it applicable to diagnose HCC on the basis of noninvasive criteria using 4-phase multidetector CT or liver dynamic  
 contrast-enhanced MRI? Should this only be done for patients with liver cirrhosis?
2. What is the size limit for a lesion for noninvasive diagnostic criteria?
3. What is the accuracy of noninvasive diagnostic criteria for a subcentimeter lesion with typical enhancement?
4.  Can we use dynamic Gd-EOB-DTPA contrast-enhanced MRI as a surveillance test? Can it be allowed as a first-line test  
 for a lesion identified by ultrasonography?
5.  Can low signal intensity on the hepatobiliary phase of dynamic Gd-EOB-DTPA contrast-enhanced MRI be accepted as  
 a parameter for noninvasive diagnostic criteria?
6. Should T2-weighted or diffusion-weighted imaging be included as a parameter for noninvasive diagnostic criteria?
7. Is contrast-enhanced ultrasound acceptable as a method for noninvasive diagnostic criteria?
8. How long should be the intervals between follow-up CT for patients with HCC?
9. Is radiofrequency ablation comparable with surgical resection for HCC with respect to survival?
10.  When does combination therapy of radiofrequency ablation and transarterial chemoembolization have advantage over  
 radiofrequency ablation monotherapy?
11.  Are patients treated with radiofrequency ablation more likely to have microscopically residual disease (R1) than those  
 treated with surgical resection?
12. Does local recurrence affect long-term survival after locoregional therapy?
13. How can the technical limitations of radiofrequency ablation due to location or invisibility of lesions be overcome?
14. Is percutaneous ethanol injection safer than radiofrequency ablation for HCC adjacent to the central bile duct?
15. Does radiofrequency ablation have a role for recurred HCC following surgical resection?
16. Do newer methods of locoregional therapy such as cryoablation or microwave ablation have a role?
17. When can we recommend transarterial chemoembolization as a first-line treatment?
18.  Can we recommend transarterial chemoembolization as a curative therapy for HCCs that are curable but not amenable  
 to other curative treatments?
19. Can we recommend transarterial chemoembolization for advanced HCCs with vascular invasion or metastasis?
20. Is there a role of chemolipiodolization?
21.  Is there a role of combination therapy of transarterial chemoembolization and other therapies such as radiofrequency  
 ablation, percutaneous ethanol injection, radiotherapy, and sorafenib?
22.  When can we recommend drug-eluting bead transarterial chemoembolization? Does it have any advantage over  
 conventional transarterial chemoembolization, or can we recommend it as a standard therapy?
23.  Is transarterial radioembolization safe? When can we recommend transarterial radioembolization? Does transarterial  
 radioembolization gain any advantage or survival benefit over conventional transarterial chemoembolization? Is it useful  
 for downstaging prior to liver transplantation? Can we recommend it as a standard therapy?
Radio-oncology
1. When can external-beam radiotherapy be performed? What are the indications for external-beam radiotherapy?
2.  Does combined radiotherapy play a role in the treatment of localized HCCs where transarterial chemoembolization is  
 not expected to be effective?
3. Can we recommend external-beam radiotherapy for HCC with portal vein tumor thrombosis?
4.  Can we recommend external-beam radiotherapy for HCCs < 5 cm not amenable to surgical resection or locoregional  
 therapy?
5. Can we recommend external-beam radiotherapy to alleviate pain or symptoms caused by distant metastases?
6. Can external-beam radiotherapy play a role in bridging therapy in advanced HCCs prior to surgical resection? 
7. Can we treat advanced HCCs with a combination of external-beam radiotherapy and systemic chemotherapy? 
CT = computed tomography, HCC = hepatocellular carcinoma, Gd-EOB-DTPA = gadolinium ethoxybenzyl diethylenetriamine pentaacetic 
acid, MRI = magnetic resonance imaging, PET = positron emission tomography
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Appendix 5. Liver Dynamic Contrast-Enhanced MRI Requirements for Assessment of HCC
Characteristic Specification Comment
MRI equipment ≥ 1.5 T
Contrast agent
Gadolinium-based agents or hepatobiliary-specific 
  agents (gadolinium ethoxybenzyl diethylenetriamine 
  pentaacetic acid)
Necessary to inject the manufacturer’s suggested 
  dose of contrast agent at a rapid rate of 1–3 mL/ 
  sec
Required imaging 
  technique
1. T2-weighted image
2. In/opposed phase T1-weighted image
3. Diffusion-weighted image
4.  Fat-suppressed three-dimensional T1-weighted  
 image before and after contrast administration
Necessary for the patient to hold their breath for  
  approximately 20 sec for optimal dynamic MRI
Dynamic phases and timing 
  required for dynamic 
  contrast-enhanced MRI
1. Late arterial phase
2. Portal venous phase
3. Delayed or transitional* phase
1. 5 sec after maximum aortic enhancement
2.  1 min after contrast injection (35–55 sec after  
 the arterial phase)
3.  2–3 min after contrast injection (optimal  
 timing is 3 min)
* It is called the transitional phase because it 
is enhanced by hepatocyte-specific uptake for 
hepatobiliary-specific contrast agents.
Hepatobiliary-specific contrast agent is helpful for  
  detecting small HCCs because it has a  
  hepatobiliary phase 10–40 min after contrast  
  injection and the liver parenchyma shows strong  
  enhancement by hepatocyte-specific uptake
Slice thickness and 
  resolution
Thickness: < 5 to –8 mm
Resolution: < 3 mm
HCC = hepatocellular carcinoma, MRI = magnetic resonance imaging
Appendix 4. Process of Revision of 2014 KLCSG-NCC Korea Practice Guideline for Management of HCC
2003 July: Release of 2003 KLCSG-NCC Korea practice guideline for the management of HCC
2009 June: Release of 2009 KLCSG-NCC Korea practice guideline for the management of HCC
2013 June: The KLCSG Chairman (SW Paik) suggested revision of KLCSG-NCC Korea guidelines
2014 September: Funding from National Cancer Center, Korea for the 2014 HCC practice guideline revision (grant #1311250, P.I. JW Park)
2014 October: The KLCSG and NCC Korea approved the 2014 KLCSG-NCC Korea HCC Practice Guideline Revision Committee (PGRC)
2013 October: Opening and workshop of the HCC PGRC at Seoul National University Hospital
2013 November–2014 April: General meetings and communications between subcommittees
2014 April: Advisory board meeting
Advisory board members: Byung Ihn Choi (Seoul National University), Byung Chul Yoo (Sungkyunkwan University),  
 Cheol Keun Park (Sungkyunkwan University), Kwang Hyub Han (Yonsei University), Hee Jung Wang (Ajou University),  
 Yun Hwan Kim (Korea University), Kwan Sik Lee (Yonsei University), Seung Woon Paik (Sungkyunkwan University)
2014 May: Public hearing at Clinical Research Institution Auditorium, Seoul National University Hospital
2014 June: Both the KLCSG board of directors and NCC, Korea approved the final manuscript of HCC guidelines
2014 June 14:  Release of 2014 KLCSG-NCC Korea Practice Guideline for the Management of HCC at the general meeting of KLCSG annual  
 conference, Jeju province
HCC = hepatocellular carcinoma, KLCSG = Korean Liver Cancer Study Group, NCC = National Cancer Center
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Appendix 6. Liver Dynamic Contrast-Enhanced CT Requirements for Assessment of Hepatocellular Carcinoma
Characteristic Specification Comment
CT imaging equipment Multidetector CT scanner with ≥ 4 detectors
Contrast agents Contrast agents at a concentration of ≥ 300 mgI/mL
Necessary to rapidly inject contrast agent at 
  a dose of 520–600 mgI/kg at 2–5 mL/sec 
Dynamic phases and timing 
  required for dynamic 
  contrast-enhanced CT
1. Late arterial phase
2. Portal venous phase
3. Delayed phase
1. 15–20 sec after maximum aortic enhancement
2. 60–80 sec after contrast injection
3.  2–3 min after contrast injection  
 (optimal timing is 3 min)
Slice thickness/reconstruction
  interval
Thickness: 5 mm
Interval: 50–100% of thickness
CT = computed tomography
